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ABSTRACT
Human placenta is a readily available source for isolation of adult mesenchymal stem cell
(MSC), for potential use in regenerative therapies. MSC fate is influenced by the
microenvironment in vivo, and insulin-like growth factors (IGFs) are critical components
of the stem cell niche, as they regulate proliferation and differentiation into different
lineages including bone, fat, and skeletal muscle. Insulin-like growth factor binding
protein-6 (IGFBP-6), relative to other IGFBPs, has high affinity for IGF2 and is believed
to be the main modulator of IGF-2 function. However, the role of IGFBP-6 in muscle
development has not been clearly defined. In this study, we investigated the role of
IGFBP-6 in different stages of muscle commitment and differentiation using human
mesenchymal stem cells derived from the placenta (PMSCs). Our central hypothesis is
that IGFBP-6 regulates the maintenance of multipotency in PMSCs and also promotes
PMSC differentiation into muscle via intracellular and extracellular interactions in both
IGF-dependent

and

independent

mechanisms.

We

used

immunoblotting,

immunocytochemistry, ELISA, and ALDH-activity to evaluate IGFBP-6 effects on
PMSC muscle differentiation. We showed that PMSCs are capable of differentiating into
muscle cells when exposed to muscle-specific differentiation medium characterized by
the decrease of pluripotency-associated markers (OCT4 and SOX2) and the gain of
expression of muscle markers Pax3/7, MyoD, Myogenin, and Myosin heavy chain in a
time-dependent manner and eventually forming multi-nucleated fibers. Extracellular
supplementation with IGFBP-6 during culture increased muscle differentiation markers
levels in early stages. The opposite effects were observed when IGFBP-6 was silenced
and was rescued by increasing IGFBP-6. We also showed that IGFBP-6 had impact on
i

muscle differentiation in both IGF-dependent and -independent mechanisms. IGF-1 and
IGF-2 had different effects on muscle differentiation with IGF-1 promoting multipotency
and early commitment to muscle, whereas IGF-2 promoting muscle differentiation.
Muscle differentiation required activation of both AKT and MAPK pathways.
Interestingly, we demonstrated that IGFBP-6 could compensate for IGF-2 loss and help
enhance the muscle differentiation process by triggering predominantly the MAPK
pathway independent of activating either IGF-1R or insulin receptor (IR). These findings
indicate complex interactions between IGFBP-6 and IGFs in PMSC differentiation into
skeletal muscle. The most prominent effects were observed early in the differentiation
process, before muscle lineage commitment. This knowledge on how myogenesis can be
manipulated using IGFs and IGFBP-6 will aid in the development of improved muscle
regeneration therapies using stem cells from human placenta.

KEYWORDS
IGF-1, IGF-2, IGFBP-6, IGF-1R, Insulin receptor, OCT4, SOX2, MyoD, Myogenin,
Myosin heavy chain, Pax3/7, Placental mesenchymal stem cells, skeletal muscle
differentiation.
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CHAPTER ONE
INTRODUCTION

This chapter contains portions of a review that was published in Stem Cells International.
Youssef A, Aboalola D, Han V KM. The Roles of Insulin-Like Growth Factors in
Mesenchymal Stem Cell Niche. Stem Cells International 2017; vol.2017, Article
ID 9453108.
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1.1 Stem Cells

1.1.1 Overview
Many tissues contain adult multipotent stromal cells, also known as mesenchymal stem
cells (MSCs), a cell type with great potential in tissue regeneration therapies. However,
the MSC availability in most tissues is limited which demands extensive expansion in
vitro following isolation. Like many developing progenitor cell types, the function of
MSCs is affected by the surrounding microenvironment, and mimicking natural
microenvironmental cues that support multipotent or differentiated states in vivo is
essential for the successful use of MSC in regenerative therapies. Many researchers are,
therefore, optimizing cell culture conditions in vitro by altering growth factors,
extracellular matrices, chemicals, oxygen tension, and pH to enhance stem cell expansion
or differentiation. The insulin-like growth factors (IGFs) system has been demonstrated
to play an important role in MSC biology to either promote cell division (self-renewal) or
to enhance differentiation onset and outcome, depending on the cell culture conditions. In
this chapter, we will review the importance of the IGFs system and its signaling partners
during development, and describe how these pathways affect differentiation towards
multiple lineages in the MSC niche.
Currently, many degenerative diseases which are associated with organ failure are
untreatable by pharmaceuticals or organ replacement, have been impacted by the promise
of cell-replacement or tissue regenerative therapies (1). Such diseases include endocrine
diseases

(diabetes),

neurodegenerative

diseases

(Parkinson‟s,

Alzheimer‟s

and

Huntington‟s), and cardiovascular diseases (myocardial infarction and peripheral

3

vascular ischemia) or chronic conditions in the cornea, skeletal muscle, skin, joints and
bones (2). Stem cells have the potential to replace damaged cells, or to send paracrine
signals that promote the survival and function of damaged tissues (3). In addition, with
the ability to generate induced pluripotent stem cells from the recipient‟s own somatic
cells (4-6) and the availability of new gene editing technologies (e.g. CRISPR-Cas9 and
TALEN) (7,8); the power of stem cell therapy for many genetic and acquired diseases, is
closer to reality than ever before.

1.1.2 Adult Mesenchymal Stem Cells (MSCs)
Adult mesenchymal stem cells (MSCs) are multipotent cells that are highly proliferative
in culture, adherent to plastic, and differentiate into many cell types including bone, fat,
cartilage, and muscle. Unlike embryonic stem cells, MSCs have less ethical controversies
and lower tumorigenicity; however, they have restricted differentiation potential (9).
Recent research has also demonstrated rare transdifferentiation ability of MSCs from
cells of one germ layer to another (10). In addition, MSCs consistently demonstrate an
immunomodulatory effect to reduce inflammation and are able to be engrafted
successfully in therapy resistant graft-versus-host disease (3). The existence of
multipotent stem and progenitor cells in adult tissues was first described in the
hematopoietic system by Till and McCulloch in 1961 (11) and was followed by the
isolation of MSCs from bone marrow by Friedenstein in 1968 (12). Since then, MSCs
have been isolated from many mature organs and tissues including skeletal muscle (13),
adipose tissue (14), deciduous teeth (15), umbilical cord blood and placenta (16),
peripheral blood (17), and brain (18). Several biological markers characterize MSCs of
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different origins to be positive for CD73, CD105, CD29, CD44, CD71, CD90, CD106,
CD120a, and CD124, and negative for CD117, CD34, CD45 and CD14 (19-21). MSCs
have been demonstrated to differentiate predominantly into mesodermal cells including
osteogenic, chondrogenic, adipogenic (22), endothelial (23), and myogenic (24) lineages.
Also, MSCs can differentiate towards ectodermal lineages including corneal (25, 26) and
neuronal cells in vitro (27).

1.1.3 Placental Mesenchymal Stem Cells (PMSCs)
Placenta is a vital organ for the embryo, acting as the interface between the fetal and
maternal environments for the transportation of nutrients and substrates (e.g. oxygen), the
removal of metabolic waste, and the production of endocrine hormones essential for the
maintenance of pregnancy (28). Unlike the early embryo from which human embryonic
stem cells are derived, placenta is a non-controversial discarded tissue that is a readily
available source of MSCs for regenerative therapy in human patients (29, 30, 31). At 6-7
days post fertilization, embryonic mesenchymal cells infiltrate the cytotrophoblast layer.
These cells in conjunction with trophoblast stem cells, invade the maternal endometrium
for implantation and initiation of placental development (32, 33). There are four types of
tissues of the placenta from which stem cells can be isolated; amnion, chorion, umbilical
cord, and fetal membranes (32, 34, 35), each found in a different niche location with the
chorionic villi being the largest source (32, 34).
The MSCs used in this study, were isolated from the main functional unit of the placenta,
the chorionic villi (Figure 1.1). Each chorionic villus is composed of three layers of cells:
villous

trophoblast (syncytiotrophoblasts

and cytotrophoblasts), villous

stroma
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(mesenchymal cells, Hofbauer cells, and fibroblasts), and fetal vascular endothelium
(endothelial cells) (36). Chorionic villi-derived cells are the earliest fetal material
obtained for prenatal diagnosis of fetal disorders (chorionic villous sampling) (37), and
the most versatile stem cell type in the placenta (38). Furthermore, chorionic villi MSCs
or placental MSCs (PMSCs) have greater cell proliferation and differentiation capacity in
vitro compared to bone marrow MSCs (39, 40).
To define the MSC population in vitro, the International Society for Cellular Therapy
established three required criteria, namely that MSC must be a) plastic-adherent when
maintained in standard culture conditions, b) express CD105, CD73 (stromal and
vascular markers), and CD90 (fibroblast markers) and lack hematopoietic markers such
as CD45 and CD34, and c) be capable of differentiation into osteoblasts, adipocytes, and
chondroblasts in vitro (39, 41, 42). Therefore, MSCs isolated from the human placenta
must be validated before use.
In this study, PMSCs isolated from the chorionic villi of preterm placentae (15-20 weeks)
tissue were tested for MSC criteria. Cultured PMSCs were clonally selected, highly
proliferative and adherent to plastic, and positive for the mesenchymal markers CD73
and CD105 and did not express the hematopoietic marker c-kit (Appendix 4).
Furthermore, PMSCs isolated efficiently differentiated into osteoblasts and adipocytes;
confirming multipotent differentiation of PMSCs (Appendix 4). Thus, PMSCs represent a
promising cell type for the development of tissue regeneration therapy, due to early
ontogeny and multipotent potential.
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Figure 1.1. The human placenta is a source of chorionic villi derived placental
mesenchymal stem cells (PMSCs). A cross section of the placenta shows different
placental structures. The intervillous space is filled with maternal blood from maternal
arterioles for nutrient and waste exchange between the fetal and maternal circulation. The
umbilical cord carries fetal blood to the fetal capillaries within the chorionic villi, which
is the main functional interface between the maternal and fetal environments. There are
seven types of cells in the chorionic villi: endothelial cells, pericytes, mesenchymal stem
cells, Hofbauer cells, cytotrophoblasts, stromal fibroblasts, and syncytiotrophoblasts.
PMSCs are found in the perivascular region of the fetal capillaries within the chorionic
villi.

Reproduced from Pathology of the Human Placenta, 3rd Ed., Benirschke K, Kaufmann P,
Castellucci M. Pages 11 and 62. Copyright 1995, with permission from Springer.
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1.1.4 Stem Cell Niche
The stem cell “niche” is a paracellular microenvironment that includes cellular and noncellular components from local and systemic sources that regulate stem cell
multipotency, proliferation, differentiation, survival and localization (43). Stem cells are
maintained by the surrounding microenvironment via cues including physical, structural,
humoral, paracrine, autocrine, and metabolic interactions (44). Therefore, a combination
of microenvironmental signals generated during development, healing or diseases
regulate tissue regeneration leading to cell proliferation, differentiation or quiescence
(45). This thesis focuses on the role of insulin-like growth factors (IGFs) system in the
MSC niche (Figure 1.2).
Insulin-like growth factors are the early effectors that impact cell fate; therefore,
controlling the availability of growth factors in the stem cell microenvironment is
beneficial for manipulating stem cells in vitro. This study will focus on the effects of
insulin like growth factors (IGFs) and their binding proteins (IGFBPs), IGFBP-6 in
particular, as components of the stem cell niche.
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Figure 1.2. Stem cell niche. The stem cell niche is a complex compartment directing
mesenchymal stem cell (MSC) differentiation and function via cellular and acellular
components. Various signals are exchanged between MSCs, mature stromal cells, other
progenitor cell types, and the extracellular matrix containing variable soluble factors,
ECM composition, oxygen tension, and pH. Therefore, the MSC niche manipulates the
state of MSCs following growth and regeneration demand. IGFs can signal via
paracrine/autocrine (produced locally by the tissue) or endocrine (delivered by blood
supply) routes and interact with IGF-1 receptor, IGF-2 receptor, or the insulin receptor on
MSCs and other cells. IGFBPs (extracellular and/or intracellular) can modify IGF actions
and affect their stability and degradation. Other receptors and integrins are also expressed
in MSCs and can be affected by extracellular microenvironment. MSC differentiation
occurs by the shutdown of pluripotency-associated genes, such as OCT4, SOX2, and
NANOG, for the up-regulation of differentiation genes. For example, MSCs can give rise
to all mesodermal lineages depending on transcription factor expression to generate
adipose, cartilage, bone, and muscle.
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1.2

Insulin-like Growth Factor System (IGF)

1.2.1

IGF System: Ligands, Receptors and Binding Proteins

Insulin-like growth factors (IGFs; IGF-1 and -2) are small polypeptides (~7 kDa) that
regulate survival, self-renewal, and differentiation of many cell types, including stem
cells (46). In the systemic circulation in postnatal life, IGF-1 levels are regulated by
growth hormone (GH), which induces IGF expression and release by the liver and
accounts for 70-90% of circulating IGFs (47). Knockdown of Igf-I in the postnatal
murine liver resulted in a 75% reduction in circulating IGF-1 levels that was
accompanied by a compensatory 4-fold increase in GH, which can lead to insulin
resistance (48). Even in the absence of hepatic IGF-1, postnatal growth was not affected
in mice. This is likely due to extra-hepatic expression of IGFs in a paracrine/autocrine
fashion, such as in the bone, brain, lung, uterus, ovaries, adipose tissue, and muscle (49).
Under this condition, serum IGF concentrations were regulated by several factors
including gender, age, and nutrition status, leading to a variable concentration range of
IGF-1 (264-789 ng/mL) and IGF-2 (702-1042 ng/mL) in healthy individuals (50). In
prenatal (embryonic/fetal) life, the regulation of the synthesis of IGF-1 and IGF-2 by
many different organs and tissues is not well understood. Most likely, the synthesis is
regulated by local (paracrine) factors and cues such as nutrient status, oxygen tension,
extracellular matrix, and other growth factors in addition to endocrine factors.
Importantly, the IGFs are synthesized as required by the developmental and physiological
cues within the extracellular and intracellular environment. It is likely that the fate of
mesenchymal stem cells which reside in the paracellular niches in adult tissues is
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regulated by IGF signals in the tissue microenvironment.
At the molecular level, IGF-1 shares more than 60% sequence homology with IGF-2 and
50% with pro-insulin (51, 52). IGFs signal mainly via the IGF-1 receptor (IGF-1R),
which has the highest binding affinity (Kd of 1 nM) towards IGF-1, with 10-fold lower
affinity to IGF-2 (53). IGF-1R is a receptor-tyrosine-kinase (RTK) which shares a
structural homology domain with the insulin receptor (IR). In turn, IR is expressed in two
isoforms IR-A and IR-B, and can form hybrid receptors (HR-A and HR-B) with the IGF1R, which bind to both IGFs with variable affinities (54). Unlike IGF-1, IGF-2 binds to
its specific receptor, IGF-2R, and, similar to insulin, it can bind to IR-A (55). IGF-1R, IR
and HRs are mitogenic RTKs while IGF-2R is not. Therefore, different receptor and
ligand combinations can cause variable signaling outcomes, especially in stem cells. Few
studies have been reported on the effects of IGF-1 on the growth, differentiation, and
migratory capacity of MSCs (56-58); however, the expression of different IGF, insulin,
and hybrid receptors and their roles in cell potency and differentiation has not been well
studied.
Circulating IGFs are also regulated by binding to six soluble (~30 kDa) IGF-binding
proteins (IGFBPs, 1-6), which determine the bioavailability of free IGF ligand in the
vicinity of the receptors, thus modifying IGF actions (59). Under normal physiological
conditions, IGFs bind IGFBPs with greater affinity than they bind IGF-1R (60-62).
IGFBPs interaction with IGFs occurs via non-covalent binding (63) that protects them
from degradation, increases their half-life (64, 65), and facilitates delivery to specific
tissues. Therefore, IGFBPs play an important role in IGF-regulated cell metabolism,
development, and growth (66). In addition, it has become apparent that IGFBPs are
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expressed and maintained within the cellular microenvironment and have additional
functions independent of regulating IGFs (67). The goal of this thesis is to delineate the
role of IGFBPs, specifically IGFBP-6, in MSC fate-decisions.

1.2.2 IGF System: Signaling Cascades
IGF-1R is a trans-membrane tetramer receptor that exists as heterodimers composed of
two α and β hemireceptors linked by disulfide bonds in a β–α–α–β structure (68). Upon
ligand binding, the downstream signal of IGF-1R is dependent on the differential
phosphorylation of its β-subunit and the resultant tyrosine residues become available to
initiate mitogenic signals, mainly through the phosphoinositide 3-kinase (PI3K),
AKT/PKB and the extracellular signal-regulated kinase (ERK1/2) (66, 69, 70). In this
manner, IGF-1R can induce transcriptional activity to promote survival and
differentiation of MSCs (71, 72).
Upon activation of the extracellular α subunits of the IGF-1R, autophosphorylation of
tyrosine residues on the β-subunits creates high affinity binding sites for signaling
adaptor molecules and substrates. For the ERK1/2 signaling pathway, SHC interacts
directly with the IGF-1Rβ which recruits GRB2 to interact with SOS that subsequently
activates c-RAS leading to the sequential phosphorylation of RAF, MEK1/2 and ERK1/2
(51, 73-77). To activate the PI3K/AKT signaling, p85, the regulatory subunit of PI3K,
interacts directly with IGF-1Rβ independent of SHC binding (78). IRS-1 is a main target
of the IGF-1R, implicated in the mitogenic effect of IGF-1R, inhibition of apoptosis, and
transformation. Conversely, IR-1 down-regulation has been associated with the inhibition
of differentiation and the induction of apoptosis (69, 79). The phosphorylation of IRS-1
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amplifies the IGF-1R signaling by indirectly recruiting GRB2 to transduce ERK1/2
signaling (73), or p85 to transduce PI3K signaling (80). Therefore, surrounding
microenvironmental inputs that define stem cell behavior depend on IGF-1R activation
and subsequent signaling cascades.

1.2.3 The Role of IGFs in Growth and Development
During development, circulating IGF levels correlate proportionally with placental and
fetal weight, and reduced levels due to poor maternal-nutrition have been suggested to
lead to fetal growth restriction (81). In human pregnancies, IGFs play an early role in
promoting proliferation/ differentiation and preventing cell apoptosis of various types of
placental cells (72). In mice, global knockout of Igf-1 or Igf-1r causes restricted growth
(<60% of wild-type) and premature death of newborn embryos. Most pups with Igf-1r-/are unable to survive due to the lack of functional muscles required for breathing,
whereas some mouse lines with Igf-1-/- will survive with deficits in major organs (8284). On the other hand, Igf-2 knockout mice (indistinguishable between homozygous and
heterozygous) are viable at 60% birth weight of wild-type (85). Double mutants for Igf-1
and Igf-2 are severely growth-deficient (30% of wild-type) and die shortly after birth due
to respiratory failure. Although both IGFs have an additive effect in embryonic
development, IGF-1 is more important in postnatal growth, while IGF-2 is important for
prenatal feto-placental growth. Hence, IGF-1 and IGF-2 stimulate both proliferation and
terminal differentiation of many organs and tissues in developing embryos and in adult
life. Since the initial description of Igf-1, Igf-2 and Igf-1r null mice using classic
knockout methodology, mice with tissue-specific knockouts of these genes have been
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generated using the Cre/loxP conditional knockout system resulting in a range of
phenotypes (86, 87). The major differences between the models are in the tissue/cellspecificity and the timing of the null mutation (prenatal or postnatal). Most of the
conditional models are generated with gene targeting after birth to allow examination of
the role of Igf-1 and Igf-1r in postnatal development without the ability to discriminate
null mutation in stem or somatic cells. In classic knockout models, gene targeting occurs
in the embryonic stem cells, allowing us to examine the impact of Igf genes in stem cells.
However, only very few reports have investigated the impact of the knockout of Igf-1 and
Igf-1r in mesenchymal stem cells.

1.2.4 The Role of IGFs in MSC Multipotency
MSCs isolated from different tissues, such as bone marrow, adipose tissue, placental
chorionic villi and fetal membranes, consistently express and secrete IGF-1 and/or IGF-2
in vitro (88-93). Ectopic IGF-1 expression in MSCs enhanced proliferation and lowered
apoptosis (94). Basic fibroblast growth factor (bFGF) was shown to be required in
maintaining stemness and proliferation in hESCs (46, 95) and in MSCs (90, 96, 97).
Further investigation showed that this effect was mediated via the IGF system, which is
up-regulated by an autonomous expression of IGF-1R, IGF-1, and IGF-2 in umbilical
cord MSCs (96). Although both IGF-1 and IGF-2 are involved in mediating stem cell fate
changes, IGF-2 appears more prominent than IGF-1 in promoting MSC multipotency. In
hESCs, IGF-2 secreted by spontaneously differentiated autologous fibroblast-like cells in
response to bFGF was required to maintain hESC pluripotency and self-renewal via IGF1R signals (46). However, one study showed that hESCs pluripotency/self-renewal
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maintenance could be independent of IGF-2 secretion only when MSCs are used as a
feeder layer (98). A study in human dental pulp MSCs (hDSCs), confirmed that the IGF1R is required for MSC multipotency and was regarded as a selection marker for
stemness, similar to OCT4 and SOX2 (99). In placental MSCs (PMSCs), IGF-2 is upregulated by low oxygen tension and is required to maintain MSC multipotency (90, 97).
Also, in neural stem cells (NSCs), IGF-2 was shown to play an important role in
maintaining self-renewal (100) via the A-isoform of IR (IR-A), independent of IGF-1R
or IGF-2R (101). Although IGF-1R and IR can form hybrid receptors, the role of hybrid
receptor in maintaining stem cell fate (ESCs or MSCs) and pluripotency is yet to be
determined.

1.2.5 Induction of MSC towards Different Lineages
In vitro, MSC differentiation can be initiated via extrinsic stimulation by growth-factors
(102); a process that requires withdrawing maintenance growth factors and adding
differentiation-promoting growth factors and chemicals (43, 44). Differentiation factors
include: dexamethasone, 3-isobutyl-1-methylxanthine, insulin and indomethacin for
adipogenic differentiation (103); TGF-β1, insulin, transferrin, dexamethasone, and
ascorbic acid for chondrogenic differentiation (103); insulin, transferrin and selenium for
skeletal myogenic differentiation (103, 104); and dexamethasone, ascorbic acid and βglycerophosphate for osteogenic differentiation (105). Therefore, the same MSC
population exposed to different extrinsic stimuli will initiate differentiation towards a
specific cell type via activation of tissue specific transcription factors, such as SOX5/6/9
for chondrocytes, PPARγ for adipocytes, MyoD family for myoblasts, and
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RUNX2/Osterix for osteoblasts (106). Moreover, MSCs have been shown to differentiate
into lineages outside of the mesodermal lineage (neural differentiation). These complex
differentiation processes have implicated IGFs in fine-tuning transcription factor
expression and activity leading to commitment towards alternate lineages from the threegerm layers.

1.2.6 The Role of IGFs in Mesenchymal Stem Cell Fate Specification and
Differentiation

1.2.6.1 Osteogenesis
IGF-1 and IGF-2 are secreted by osteocytes for stimulation of bone formation, growth,
and metabolism and can prevent apoptosis in a paracrine/autocrine manner (107, 108).
Local overexpression of IGF-1 in osteoblasts can accelerate the rate of bone formation
and increase the pace of matrix mineralization, which is dependent on IGF-1R (109).
Decoupling

of

IGF-1R

signaling

from

IGF-1

is

responsible

for

reduced

proliferation/differentiation in primary osteoblasts from osteoporosis patients, causing
bone loss (110). Under non-differentiation conditions, IGF-1 transfected human MSCs
are able to up-regulate expression of various osteoblast genes (111). Bone marrow MSCs
(BM-MSCs) secrete IGF-1 and generate conditioned media that was sufficient to induce
alveolar bone regeneration prior to dental implant placement (112). In dental pulp MSC,
IGF-1 was shown to promote mTOR signaling pathway and trigger the expression of
RUNX2, OCN, OSX, and COL1 (57). Also, human deciduous teeth MSCs with high
osteopotential express and secrete IGF-2 that is required for differentiation and
mineralization (113). Overall, IGF-1 and IGF-2 play a significant role in MSC osteogenic

16

differentiation and bone health.

1.2.6.2 Myogenesis
L6E9 cells, a myoblast cell line used in myogenesis studies, with IGF-1 induces an initial
proliferative response (114). During rapid cell division, myogenic regulatory factors are
inhibited, but 30 hours later, the mitogenic effect is suppressed and Myogenin expression
and activity are increased. Although, the downstream factors in IGF-mediated
differentiation are still under investigation, IGFs can induce myogenic transcription
factors expression. Moreover, the overexpression of MyoD (a protein that plays a major
role in regulating muscle differentiation) in C3H 10T1/2 mouse embryonic fibroblast
cells induced IGF-2 expression, which in turn activated IGF-1R and its downstream
target AKT (115). Specifically, IGF-2 was required for the recruitment and induction of
myogenic promoters and myogenesis (116). In particular, IGF-2 was required to allow
continued recruitment of MyoD-associated proteins at the Myogenin promoter (117). The
IGF-2 specific binding protein, IGFBP-6, is expressed during embryonic development in
many different tissues including the ossifying bones of the cranium, myoblasts and the
motor neurons of the spinal cord (118).
The potential use of MSCs has been previously investigated in treating muscular injury,
including myocardial infarction. Rat BM-MSCs release paracrine factors that can be used
to treat soleus muscle injury (119). Treatment of MSCs with IGF-1 improved MSCinduced muscle healing by reducing scar formation, increasing angiogenesis, recovery of
muscle structure, and improving function (119). Injection of BM-MSC into the cardiac
muscle increased the proliferation, migration and inhibited apoptosis of existing cardiac
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muscle cells after myocardial infarction; however, IGF-1 did not induce myocardial
differentiation of these MSCs (120). In addition, transplantation of IGF-1-primed MSCs
attenuated cardiac dysfunction, increased the survival of engrafted MSCs in the ischemic
heart, decreased myocardium cell apoptosis, and inhibited the expression of inflammation
cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-1β, and IL-6 (121).
The current research into MSCs and IGF in myogenesis is, therefore, more focused on in
vivo muscle repair rather than MSC-differentiated myoblast replacement after
transplantation.

1.2.6.3 Adipogenesis
In a comparative study of MSCs from different sources including adipose (ASCs), bone
marrow (BMSCs), dermal sheath cells (DSCs), and dermal papilla cells (DPCs), IGF-1
had the highest expression and secretion in ASC desired populations (122). Furthermore,
IGF-1 was shown to alter MSC fate between osteogenic and adipogenic lineages via its
ability to bind and form a complex with the acid-labile subunit (ALS) (123). The loss of
this IGF-1/ALS complex shifted differentiation from osteogenesis to adipogenesis (123).

1.2.6.4 Chondrogenesis
In a study of intervertebral disc degeneration, it was shown that IGF-1 and TGF-β3 work
in synergy to enhance nucleus pulposus-derived MSCs viability, extracellular matrix
biosynthesis and differentiation towards nucleus pulposus cells (124). Although TGF-β
signaling is known to be important for chondrocyte-inductive differentiation from MSCs,
other studies show that IGF-1 can regulate MSC chondrogenesis independent of TGF-β.
In one study, IGF-1 induced chondrogenic differentiation from adipose-derived MSCs as
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evident by increased collagen type II, aggrecan, and SOX9 expression (58). Similarly,
IGF-1 induced the chondrogenic potential of BM-derived MSCs stimulating proliferation
and inducing expression of chondrogenic markers (125). In addition, IRS-1 localization
was induced from nuclear to cytoplasmic to shift MSC proliferation to differentiation
(126).

1.2.7 Crosstalk between the IGF Axis and Other Signaling Pathways in MSC
Proliferation and Differentiation
Crosstalk between signaling pathways are important for stem cells self-renewal and
differentiation; however, specific interactions with the IGF system are still being
delineated in MSCs. As shown in Figure 1.1, integrins can play an important role in IGF
signaling. In particular, IGF-1 directly binds to αvβ3 integrin and induces αvβ3-IGF1IGF1R ternary complex formation required for phosphorylation, ERK and AKT
activation and cell proliferation (127).
During bone formation and osteoblast differentiation, IGF-2 potentiates bone
morphogenetic protein-9 (BMP-9) signaling, which belongs to the transforming growth
factor-β (TGF-β) superfamily (128). IGF-2 stimulation of PI3K/AKT can potentiate
BMP-9-induced activity of alkaline phosphatase (ALP) a marker of early osteogenesis
and the expression of later markers such as osteocalcin and osteopontin in MSCs.
Interestingly, IGFBP-3 and IGFBP-4 inhibit these effects (128).
During osteoblast differentiation of BM-MSCs, hedgehog (HH) via Gli2 was shown to
increase IGF-2 expression acting via the IGF-1R/mTORC2/AKT pathway (129). IGF-2mediated AKT activation served as a positive feedback loop for enhanced HH
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transcriptional output by stabilizing full length Gli2 due to phosphorylation by AKT. In
myogenic differentiation, sonic hedgehog (SHH), was also regarded as a positive
regulator of IGF-1 signaling with a cooperative additive effect in primary myoblast
proliferation and differentiation via the MAPK/ERK and PI3K/AKT pathways (130).
Crosstalk between the IGF system and other pathways has also been explored in cancer
stem cells, which may not be dependent on their immediate niche, but can give an insight
into normal stem cell signaling (131). In glioma stem cells (GSC), HH via Gli1 upregulated the transcriptional activation of IRS-1 which increased GSC sensitivity to IGF1 stimulation (132). In lung adenocarcinoma stem-like cells, IGF-1R-mediated-OCT4
expression to form a complex with β-catenin and SOX2 that was crucial for self-renewal
and oncogenic potential (133).

1.2.8 IGF-Expressing MSCs for the Treatment of Terminal Diseases
Paracrine factors, including IGFs, secreted by MSC are shown to play a major role in
treating

organ-failure

diseases.

IGF-expressing

MSCs

enhance

proliferation,

differentiation and repair of surrounding tissue in kidney, heart, and pancreas (91-93). In
kidney ischemic-reperfusion injury, physical interaction between MSC and kidney tissue
was required to promote kidney repair (93). Following myocardial infarction, adult
human epicardium-derived cells and cardiomyocyte progenitor cells synergistically
improve cardiac function, likely instigated by complementary paracrine actions (134). In
fact, co-transplantation of unmodified MSC with cardiovascular progenitors elevated the
expression of factors promoting cardiac repair. Specifically, IGF-1 promoted expression
of pro-survival and angiogenesis genes in human cardiomyocyte progenitors (135).
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In STZ-induced hyperglycemic mice, MSC helped in wound healing via IGF-1 secretion
(136). IGF-1 in these mice activated PI3K/AKT and GLUT4, which improved glucose
uptake and insulin sensitivity, thereby improving diabetic wound healing. In
hepatocellular carcinoma (HCC), fetal human MSC conditioned media was used to
inhibit cell growth (137). It was discovered that the conditioned media contained high
levels of IGFBPs that sequestered IGFs and reduced IGF-1R and AKT activation leading
to cell cycle arrest in HCC. These tumor-specific effects were not observed in matched
hepatocytes or patient-derived matched normal tissue.

1.2.9 IGFs and in vitro MSC Differentiation
Addition of IGFs into MSC differentiation media leads to an earlier commitment and
increased differentiation of MSC into several lineages including osteoblast, adipocyte,
and chondrocyte cells (Table 1.1). In this context, a typical concentration of 10-100
ng/mL of IGF-1 is sufficient to activate only the IGF-1R and not the IR. On the other
hand, not much attention is given to receptor binding affinity of IGF-1R versus IR when
insulin is used in maintenance or differentiation conditions. Commercial media for stem
cell research include non-physiological concentrations of insulin (0.5, 5, 10 µg/mL); 1001,000 x higher than the highest insulin concentration in serum (138). High concentrations
of insulin (≥1 µg/mL) not only activate IR but also activate IGF-1R (53, 138). Therefore,
using high insulin concentrations in defined media, which can be a substitute for IGFs,
cannot distinguish whether the effect is mediated via the IGF-1R or IR signaling
pathways and studies describing the effect of IGFs in growth and/or differentiation of
stem cells in “defined medium” should recognize this potential confounding effect.
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Table 1.1 MSC differentiation protocols with IGFs towards different lineages.
Example of MSC differentiation protocols included IGFs in their differentiation media
formulations.
MSC Population

Differentiation

Protocol

Reference

Human dental pulp stem cells

Osteoblast-like cells

Osteogenic media supplemented with 0.1
µmol/L dexamethasone, 10 mmol/L bglycerophosphate and 50 µg/mL ascorbic acid
and 100 ng/mL IGF-1.

(57)

Stromal vascular fraction of
adipose tissue - human adipose
stem/progenitor cells

Adipocyte-like cells

StemPro® Adipogenesis Differentiation Kit
supplemented with 10 ng/mL of IGF-1.

(139)

Chondrocyte-like cells

DMEM high glucose supplemented with 1%
FBS, 0.1 mM ascorbic acid-2- phosphate, 10 −7
dexamethasone, 6.25 μg/ml transferrin, 6.25
ng/ml selenous acid, 10 ng/ml recombinant
human TGF-β1, 100 ng/ml recombinant human
IGF-1.

(58)

Human adipose-derived
mesenchymal cells

1.3 Insulin-Like Growth Factor Binding Protein-6 (IGFBP-6)
IGFBP-6 is a 30 kDa, secreted, O-linked glycoprotein, which unlike other IGFBPs has a
significantly higher affinity (100 fold), for IGF-2 than IGF-1 (67, 140). IGFBP-6 has
three structural domains: the C terminal domain, the L domain (for linker or labile) and
the N terminal domain. The C-terminal domain of IGFBP-6 shows a high degree of
mobility. Interestingly, the site on IGF-2 where IGFBP-6 binds overlaps with that of the
IGF-1R binding site, giving a structural basis for IGFBP-6‟s ability to inhibit IGF-2
binding to the IGF-1R (141). Although highly conserved, the N-terminal domain of
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IGFBP 1-5 contains a GCGCC motif which is not conserved in IGFBP-6. In IGFBP-6 the
two adjacent cysteine residues are missing, resulting in different disulphide linkages than
the other binding proteins (142).This difference appears to be a contributing factor to the
unique preference of IGFBP-6 for IGF-2 (142).
In addition to being a secreted protein, IGFBP-6 is also subject to proteolysis. Studies in
Madin-Darby canine kidney (MDCK) cells, an epithelial cell line derived from canine
kidney, suggest that IGFBP-6 proteolysis and the conformational change that
accompanies IGFBP-6 binding to IGF-2 may prolong degradation rates (143). The
balance between proteolysis and glycosylation of IGFBP-6 helps maintain stability in
IGF-2 binding and thus IGF-2 function modulation.

1.3.1 IGFs, IGFBP-6 and Myogenesis
Myogenesis is the process by which undifferentiated cells differentiate into muscle cells.
Muscle cells develop from the mesoderm layer of the developing embryo. Myogenesis
can be divided into three distinct stages. After completing each of these stages, the
differentiating cells express specific proteins. The expression of these proteins indicates
which stage the developing cell has passed. After specification once the cells become
muscle precursors, they express Pax3, Pax7, Gli2, and Six1 and undergo commitment to
become myoblast cells. Committed myoblasts express myogenic regulatory factors
(MRFs) as well as muscle commitment markers such as Pax3 and Pax7. After
commitment, cells undergo terminal differentiation and become myocytes that express
early muscle differentiation markers (Myf-5, MyoD, and Myogenin) followed by late
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muscle lineage differentiation marker myosin heavy chain (MHC) and the formation of
multi-nucleated fibres (144-148).
The myogenic regulatory factors (MRFs) each serve distinct but overlapping roles in
muscle development. Mice develop skeletal muscle normally when either Myf-5 or
MyoD are lacking. The loss of myf-5 results in an up-regulation of MyoD (149, 150).
However, when both are missing, myoblasts do not form, suggesting that Myf-5 and
MyoD have overlapping roles and can compensate for the loss of the other (151). The
loss of Myf-5 and MyoD together is perinatal lethal due to respiratory failure from a total
lack of muscles in the trunk. Myogenin is also necessary for survival. When myogenin is
lacking in mice, the mutations are also perinatal lethal, and the mice die shortly after
birth due to severe muscle deficiency and respiratory failure (152).
The IGF family has been shown to have a role in muscle development. One clear
demonstration is loss-of-function studies that have been performed. In IGF-1 or IGF-1R
knock-out mice the embryos die prematurely because the pups are unable to survive
because functional muscle is completely lacking and thus they are unable to breathe (82,
86).When MyoD is expressed in C3H 10T1/2 mouse embryonic fibroblast cells, there is
an induction of IGF-2 expression and activation of the IGF-1R (116). After muscle
injury, IGF-1 enhances regeneration while inhibiting IGF-1 reduces the number of
regenerating myofibers in vivo (153). IGF-2 is expressed abundantly in the developing
skeletal muscle and is the major growth factor for muscle growth, differentiation, and
regeneration (154, 155). These studies suggest an important role for IGF peptides and the
IGF-1R in the regulation of myogenesis. However, the downstream factors involved in
IGF stimulated differentiation still remain elusive.
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IGFBP-6 is expressed during embryonic development in myoblasts (156). Previous
studies in the Han Laboratory showed that rhabdomyosarcoma cells (RD cells) treated
with mutant (non-nuclear) IGFBP-6 undergo terminal differentiation at a rate of 0.05%
compared to 0% of the un-transfected RD cells or wild-type IGFBP-6 expressing cells, as
measured by the immunoreactivity of myosin heavy chain (157). This percentage is
significant since control (un-transfected or empty vector transfected) RD cells and wildtype IGFBP-6 expressing RD cells never underwent myogenesis. No previous studies
have been performed on the role of IGFs and IGFBP-6 on PMSCs differentiation into
skeletal muscle.
The need to find a stem cell population with the proper niche factors that will eliminate
the difficulties related to other stem cells used before to try and treat muscle diseases like
Duchene muscular dystrophy in tissue regeneration therapy is important. Therefore, I
propose to further delineate the extracellular and intracellular molecular mechanisms that
trigger the process of skeletal muscle differentiation from placental mesenchymal stem
cells by IGFBP-6 and the IGF system.

1.4 Thesis Rationale
The expression of IGFBP-6 is associated with non-proliferative states such as cell
differentiation (158). Also, IGFBP-6 over-expression in cells has either a growthpromoting or a growth-inhibitory effect, depending on the cell type (159, 160). To date,
no studies have been performed on IGFBP-6 and PMSCs. Moreover, the conflicting data
about IGFBP-6 in other cell lines raises questions about how this binding protein will
function in PMSCs and how it affects the fate of these cells.
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During development, IGF-2 and IGFBP-6 are expressed abundantly in developing
muscle cells and are required for myogenesis (155). Furthermore, IGF-1 and IGF-2 are
expressed by skeletal muscle cells during muscle repair in response to muscle injury
(154, 155).
Testing if myogenesis can be manipulated by the IGF system, specifically IGFBP-6
expression, and delineating the mechanisms involved during muscle differentiation will
help us understand the complex processes of embryonic development and improve
muscle regeneration therapies. As no previous studies have been performed on IGFBP-6
and PMSCs, my novel research project is focused on understanding IGFs and IGFBP-6
role in PMSC differentiation into skeletal muscle (Figure 1.3).
Increasing IGFBP-6 in the PMSC extracellular microenvironment is expected to
sequester IGF-2 and prevent MSC differentiation. Conversely, silencing of IGFBP-6
expression is expected to increase PMSC differentiation, as a result of a greater
availability of IGF-2 (117, 161). In addition, IGFBP-6 is known to be present in the
cytoplasm and in the nuclei (162, 163) suggesting that IGFBP-6 may have IGF-2
independent functions.
Knowledge of IGFBP-6 effects on muscle differentiation will help explain the
mechanisms controlling stem cell fate in the presence of IGFs and improve strategies for
skeletal muscle regeneration therapies using placental mesenchymal stem cells in
diseases, such as muscular dystrophy, to improve muscle regeneration.
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1.5 Hypothesis and Objectives
Our central hypothesis is that IGFs and IGFBP-6 regulate the differentiation of PMSCs
into skeletal muscle via intracellular and extracellular mechanisms.
This hypothesis will be addressed in the following 4 aims:
1. To evaluate the extracellular and intracellular effects of IGFBP-6 on the differentiation
of PMSCs into skeletal muscle.
2. To determine the interaction between IGFs and IGFBP-6 on PMSCs skeletal muscle
differentiation.
3. To investigate the IGF-dependent and IGF-independent actions of IGFBP-6 on PMSCs
muscle differentiation.
4. To identify the signal transduction mechanisms of IGFBP-6 on muscle differentiation
by PMSCs.

In these studies, we showed that the human placenta is a valid source of multipotent
MSCs and that the IGF signaling axis, specifically involving IGFBP-6, is important in
muscle differentiation. Understanding IGFs and IGFBP-6 effects on muscle
differentiation will help improve strategies for skeletal muscle regeneration therapies
using stem cells to treat muscle degeneration.
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1.6 Summary and Conclusions
IGFs are one of the earliest growth factors to be expressed in the pre-implantation
embryo and putatively act as autocrine/paracrine factors in many developing cell types,
including stem cells. They form an important component of the stem cell niche. Their
expression is ubiquitous in many cell types; however, they are most abundant in cells and
tissues of mesodermal origin. Thus, MSCs are both the source and target of IGFs during
development, and likely play important roles in determining cell fate. Recent evidence
also suggests the potential discriminating roles of IGFs in MSCs. As MSCs are being
investigated in the context of cellular replacement and regenerative therapies, delineating
the roles of endogenous as well as exogenous IGFs in MSC growth and differentiation
will be critical in developing these cellular therapies to treat degenerative diseases.
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Figure 1.3. Myogenic lineage progression. Muscle development is regulated by a
number of transcription factors. Six1/4 and Pax3/7 are master regulators of early
myocytes lineage commitment to the myogenic lineage, whereas Myf5, MyoD, and
MyoG represent early differentiation markers. Expression of the terminal differentiation
genes, required for the fusion of myocytes and the formation of myotubes, is mediated by
myosin heavy chain (MHC).

Reproduced from Building muscle: molecular regulation of myogenesis. Bentzinger CF, Wang
YX, Rudnicki MA. Page 6. 2012;4:a008342, with permission and copyright to Cold Spring
Harbor Laboratory Press.
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2.1 INTRODUCTION
Unlike embryonic stem cells which are derived from the early embryo, placental
mesenchymal stem cells (PMSCs) are derived from human placentae which are usually
discarded, and therefore are readily available source of adult stem cells for use in tissue
regenerative therapies in human patients (1,2,3). PMSCs are available in large numbers
in vitro (3). Importantly, the pathways activated by these cells during differentiation into
specific cell types in vitro and in vivo may provide important information on the
developmental and regenerative processes of tissues and organs during embryogenesis
and later development in adults.
Skeletal muscle development is a highly coordinated, step-wise process utilizing a series
of transcription factors, and structural and enzymatic proteins that mark the different
stages of skeletal muscle development. During myogenesis, committed progenitors
differentiate into muscle lineage by up-regulating myogenic regulatory factors (MRFs) as
well as muscle commitment transcription factors (Pax3 and Pax7), followed by the
expression of early muscle cell structural components (MyoD and Myogenin) (4). After
commitment, cells fuse together to form multinucleated fibers and express muscle
specific proteins, such as myosin heavy chain (MHC) (4). It is believed that in recovery
and regeneration after muscle injury in the adult, this process is recapitulated.
The insulin-like growth factor (IGF) family of peptides regulates cell growth,
differentiation and the maintenance of cell survival through several signal transduction
pathways (5). This family includes two IGF peptides (IGF-1 and IGF-2), three cell
surface receptors (type-1, type-2 IGF receptors, and insulin receptor) and six IGF binding
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proteins (IGFBPs) (5). IGF-1 and IGF-2 are circulating peptides that function as potent
mitogens for many cell types, mediated by binding to IGF-1R, a membrane receptor
tyrosine kinase (6). IGFBPs are carriers for IGFs in the circulation and in the
extracellular fluid compartment (7), protecting them from degradation (6, 8), delivering
them to specific tissues, and modulating the biological actions of IGFs.
IGFBP-6 is a 30 kDa secreted protein, and unlike other IGFBPs, has a significantly
higher affinity (~70-100 fold) for IGF-2 than IGF-1 (9, 10). IGFBP-6 has been
demonstrated to modulate IGF-2 activity via inhibition of IGF-2 binding to the IGF-1R
or directly independent of IGF-2 (11, 12). IGF binding proteins, including IGFBP-6, are
also localized within the intracellular environment, suggesting that IGFBPs may have
biological actions independent of the IGFs (13).
The IGF family has been shown previously to play a major role in muscle development.
IGF-1R knockout mice die soon after birth due to breathing difficulties due to lack of
functional respiratory muscles (14, 15). IGF-2 is expressed abundantly in the developing
skeletal muscle and is a major factor for muscle growth, differentiation, and regeneration
(16). When IGF-2 is knocked down, myogenesis does not occur (16). During
development, IGFBP-6 is expressed abundantly in developing muscle cells and is also
required for myogenesis (16). Previous studies in our laboratory have described IGFindependent functions of IGFBP-6 on regulating Ku proteins and thus effecting cell fate
in a skeletal muscle cell line (17). Other studies have shown that IGFBP-6 inhibits
angiogenesis but promotes migration in an IGF-independent manner (11).
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To our knowledge, no previous studies have reported on the biological roles of IGFBP-6
in the differentiation of MSCs into the muscle lineage. In this study, we characterized the
effects of IGFBP-6 on the differentiation of PMSCs into skeletal muscle.

2.2 MATERIALS AND METHODS

2.2.1 Isolation of PMSCs
PMSC isolation and experiments were conducted with the approval from the Health
Sciences Research Ethics Board of Western University (REB# 12154). Informed consent
was obtained from healthy women undergoing therapeutic termination of pregnancy, and
the PMSCs used in this study were isolated from one 15 week preterm placental tissue.
After surgery, chorionic villi were dissected, washed, and minced with surgical scissors
and forceps, and then subjected to enzymatic digestion with collagenase IV (369 IU/mg),
hyaluronidase (999 IU/mg) (Sigma-Aldrich, Oakville, ON), and DNase I (2,000 IU/mg)
(Hoffmann-LaRoche, Mississauga, ON) for 10 minutes at room temperature, followed by
0.05% trypsin (Gibco/Invitrogen, Mississauga, ON) for 5 minutes at room temperature.
The sample was then washed for 10 minutes with 10% FBS in DMEM/F12 medium and
the resulting single cell suspension was separated by density centrifugation over a Percoll
(Sigma-Aldrich, Oakville, ON) discontinuous gradient using a modified protocol by
Worton et al. (18).

2.2.2 Cell Culture
Cells from Percoll gradient fractions #3 and #4 were plated on to T75 flasks, cultured,
and maintained using DMEM/F12 media supplemented with 15% FBS serum
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(Gibco/Invitrogen, Mississauga, ON) and FGF-2 (50 ng/mL) (Sigma-Aldrich, Oakville,
ON) containing 100 U/mL Penicillin, 100 µg/mL Streptomycin, and 0.25 µg/mL
Amphotericin-B. The non-adherent cells were discarded at the time of media change,
which was performed every 72 hours. The adherent cells were cultured until they reach
90% confluence. Cells were then passaged 1:2 approximately once per week using 0.05%
Trypsin for 10 min at 37°C for 3 passages. Passaged cells were stored at -80°C in 1 mL
of freezing media (30% FBS and 10% DMSO in DMEM/F12 media). When needed,
vials were thawed and cells were resuspended in normal culture media (25 ng/mL FGF-2
and 15% FBS in DMEM/F12).

2.2.3 Muscle Differentiation
Cells were plated in muscle growth media (fetal bovine serum 0.05 mL/mL, fetuin 50
µg/mL, epidermal growth factor 10 ng/mL, basic fibroblast growth factor 1 ng/mL,
insulin 10 µg/mL, and dexamethasone 0.4 µg/mL) for 48 hours before changing to the
skeletal muscle differentiation media, which is a proprietary serum-free medium
containing 10 µg/mL insulin (PromoCell, Heidelberg, Germany). Cells were grown in
six-well plates for 14 days in a standard tissue culture incubator at 37°C in 5% CO2.

2.2.4 IGFBP-6
Recombinant human IGFBP-6 (PROSPEC, East Brunswick, NJ) was resuspended in
sterile MilliQ-H2O and supplemented to the media at a concentration of 375 ng/mL.
IGFBP-6 concentration was determined by a dose response experiment using PMSCs in
muscle differentiation media (Figure S2.1A). IGFBP-6 was added every 3 days at the
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time of media change because that was the time it took for IGFBP-6 secreted levels to be
lower than the control (Figure S2.1B).

2.2.5 Down-Regulation of IGFBP-6 Expression by siRNA
To silence endogenous IGFBP-6 expression in PMSCs, siRNA against IGFBP-6 (Santa
Cruz Biotechnology, Dallas, TX) was used. 8 μL of Lipofectamine (Invitrogen,
Mississauga, ON) with either 8 μL of scrambled or IGFBP-6 siRNA was added to 100
μL of DMEM/F12 media (Invitrogen, Mississauga, ON) for 40 minutes at room
temperature; the final concentration of siRNA was 80 nM. The siRNA solution was then
added to 60% confluent cells and incubated for 5 hours at 37ºC. Muscle growth media
(1.5 mL) was added to the cells for 48 hours and subsequently replaced with 2 mL of
muscle differentiation media. New siRNA was added every 3 days during the change of
media and the experiment was performed for 7 days.

2.2.6 Immunocytochemistry
PMSCs were grown on glass cover slips (80-90% confluence), stained with primary
antibodies (1:100), and incubated at 4°C overnight. To detect markers of cell potency,
OCT4 (N-19: sc-8628) (Santa Cruz Biotechnology, Dallas, TX) was used. To detect
markers of muscle differentiation, Myosin heavy chain (H-300: sc-20641) (Santa Cruz
Biotechnology, Dallas, TX) was used. To detect IGFBP-6, antibody H-70: sc-13094
(Santa Cruz Biotechnology, Dallas, TX) was used. Primary antibodies were washed using
0.1% Tween-20 in PBS (3 times for 5 minutes). Cells were then incubated in the dark
with the corresponding secondary AlexaFluor conjugated antibody (1:200). The
secondary antibodies used were AlexaFluor 488 or AlexaFluor 568 conjugated antibodies
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(Invitrogen, Mississauga, ON). The secondary antibody was washed 0.1% Tween-20 in
PBS, and the nuclear stain (Hoechst dye) was added for 7 minutes and then rinsed. The
cover slips were mounted and images were taken using a confocal microscope (Zeiss,
Germany). Each antibody was performed in triplicate.

2.2.7 Cell Lysate Preparation
Following PMSC treatments, cells were washed with DPBS (Gibco/Invitrogen,
Mississauga, ON) and 200 μL of (1x) cell lysis buffer (Cell Signaling Technologies,
Burlington, ON) mixed with protease and phosphatase inhibitors (1:100) were added to
the cells. Cells were detached using a cell scraper and the lysate was sonicated for 15
seconds. Finally, samples were centrifuged for 15 minutes at 14,000 rpm at 4°C, and the
supernatant was collected.

2.2.8 Immunoblotting
Cell lysates containing 20 µg of protein were added to 6x SDS gel loading buffer (1% βmercaptoethanol, 1% SDS, 30% glycerol, 0.0012% bromophenol blue, Tris HCl 0.28 M,
pH 6.8). Samples were boiled for 5 minutes at 95oC, then placed on ice for 3 minutes,
and centrifuged at 3,000 rpm for 20 seconds before loading. Samples were resolved by
molecular weight using 10% SDS polyacrylamide gels transferred onto poly-vinyl-denefluoride (PVDF) membranes (Bio-Rad, Hercules, CA) using a Trans-Blot Turbo (BioRad, Hercules, CA) with an optimized protocol depending on protein size. Membranes
were blocked with 5% non-fat-dry milk, gently shaking for 1 hour at room temperature in
Tris-HCl buffer saline pH 8.0 with 0.1% Tween-20 (TBS-T). Blots were then washed
with TBS-T (3 times for 10 minutes) followed by incubation at 4°C overnight with
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specific primary antibodies in 5% BSA or 5% non-fat-dry milk in TBS-T following the
manufacturer‟s protocol. To detect markers of cell potency markers, antibodies for OCT4
(N-19: sc-8628) (Santa Cruz Biotechnology, Dallas, TX), and SOX2 (2683-1)
(Epitomics, Burlington, ON) were used. To detect markers of muscle differentiation,
Pax3/7 (E-10: sc-365613), MyoD (M-318: sc-760), Myogenin (F5D: sc-12732), and
Myosin heavy chain (H-300: sc-20641) (Santa Cruz Biotechnology, Dallas, TX) were
used. To detect IGFBP-6, antibody H-70: sc-13094 (Santa Cruz Biotechnology, Dallas,
TX) was used. For loading control, pan-Actin Ab-5 (Thermo Fisher Scientific, Fremont,
CA) was used.
Then membranes were washed and incubated for 1 hour at room temperature with the
corresponding secondary HRP-conjugated antibody. The secondary antibodies used were
HRP-conjugated goat anti-rabbit (#170-6515) or anti-mouse (#170-6516) (Bio-Rad,
Hercules, CA) or donkey anti-goat antibody (Santa Cruz Biotechnology, Dallas, TX).
Resolved protein bands were detected using chemiluminescence and images were taken
using the VersaDoc Imager (Bio-Rad, Hercules, CA). Western blots were performed in
triplicate.

2.2.9 Quantification of IGFBP-6 and IGF-2 Secretion by Enzyme-Linked
Immunosorbent Assay (ELISA)
Human IGFBP-6 (RayBiotech®, Burlington, ON) and IGF-2 (ALPCO, Salem, NH)
ELISA kits were used to measure the amount of IGFBP-6 and IGF-2 secreted into the
conditioned media for 14 days. Standards and samples were loaded into the wells (in
triplicate) and the immobilized antibody bound IGFBP-6 or IGF-2 present in the sample.
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The wells were washed and biotinylated anti-human antibody was added. After washing,
HRP-conjugated streptavidin was added; then a TMB substrate solution was used to
develop a blue color in proportion to the amount of IGFBP-6 or IGF-2 bound. Then, a
Stop Solution was added, which changed the color from blue to yellow, and the intensity
was measured at 450 nm using Multiskan Ascent plate reader and analysis software.

2.2.10 Aldehyde Dehydrogenase (ALDH) Activity
ALDH-activity, a conserved progenitor cell function, was assessed by flow cytometry for
14 days. Using the AldefluorTM assay (Stem Cell Technologies, Vancouver, BC), as per
the manufacturer‟s instructions. Briefly, 5 μL of activated Aldefluor reagent was added to
1 mL of cell suspension and incubated for 45 minutes at 37°C. Cells were washed and
resuspended in 500 μL of ice-cold Aldefluor assay buffer and ALDH-activity was
measured using flow cytometry. As a negative control, AldefluorTM DEAB reagent was
used. Samples were run in triplicate.

2.2.11 Statistical Analysis
All experiments were performed in triplicate from one 15 week placental tissue (technical
replicate). GraphPad Prism Software 5.0 was used to generate all graphs and analyses. A
two-way ANOVA followed by a Bonferroni‟s multiple comparison test or a one-way
ANOVA followed by a Student‟s t-test was used to calculate significant differences when
p<0.05. Graphic representation values are presented as mean ± SEM (shown as variance
bars).
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2.3 RESULTS

2.3.1 PMSCs can Differentiate into Skeletal Muscle
To determine if PMSCs can differentiate into skeletal muscle, PMSCs were grown under
muscle differentiation conditions for up to 14 days. Compared to PMSCs grown in nondifferentiating conditions (10% FBS), differentiated PMSCs showed muscle morphology
as early as day 1 post-differentiation (compaction and elongated appearance) (Figure
2.1A and 2.1B), and cells continued to differentiate forming multi-nucleated fibers at day
14 (Figure 2.1C, 2.1D and S2.2A). Associated with these morphological changes,
pluripotency-associated marker (OCT4) immunoreactivity appeared low (Figure 2.1E,
2.1F, and S2.2B), and muscle differentiation marker (MHC) immunoreactivity was high
(Figure 2.1G and 2.1H) when compared to control cells (10% FBS). In addition, PMSCs
under muscle differentiation conditions showed lower cell counts per field compared to
undifferentiated controls (Figure S2.2C).
Under muscle differentiation conditions, PMSCs decreased pluripotency-associated
protein levels of OCT4 and SOX2. OCT4 levels were significantly reduced at day 1
compared to control with further decrease at 14 days post-differentiation (Figure 2.2A).
In addition, SOX2 levels were lowered and nearly diminished by day 14 in cells under
muscle differentiation conditions compared to control (Figure 2.2B). Muscle
commitment marker Pax3/7 level was increased at day 7, followed by a decrease at day
14 in PMSCs under muscle differentiation conditions compared to control (Figure 2.2C);
suggesting that PMSCs under muscle differentiation conditions are committed to the
muscle lineage and are proceeding to muscle differentiation. This was confirmed by the
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protein levels of muscle markers (MyoD, MyoG, and MHC), that increased significantly
over time under muscle differentiation conditions (Figure 2.2D, 2.2E, and 2.2F).
Collectively, these findings indicated that PMSCs differentiate into skeletal muscle under
differentiating culture conditions, and this cell differentiation model could be consistently
used to study muscle development in vitro.
We used the AldefluorTM assay to determine the frequency of primitive progenitor cells
with high ALDH-activity. In this context, high ALDH-activity is a conserved
characteristic of proliferative progenitor cells of multiple lineages (19-21). As
differentiation occurs towards a more mature cellular phenotype, ALDH-activity is
reduced. Compared to PMSCs grown under non-differentiation conditions, there was a
decrease in the frequency of cells with high ALDH-activity (ALDH+ cells) under muscle
differentiation conditions at days 1 to 14 (Figures 2.3A to 2.3D). Moreover, ALDHactivity was also decreased over time when cultured under control conditions (10% FBS)
(Figure 2.3E). These findings suggested that PMSCs comprised of a heterogeneous
population that slowly differentiated during maintenance in standard culture conditions,
and PMSCs stimulated to differentiate into skeletal muscle immediately decreased
ALDH-activity at earlier time points.
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Figure 2.1. PMSCs cultured under muscle differentiation conditions showed muscle
morphology with lower OCT4 and higher MHC at 14 days post-differentiation. (A,
B) Compared to cells cultured under standard conditions in 10%FBS, PMSCs grown in
muscle differentiation media showed skeletal muscle morphology as early as day 1 postdifferentiation (20X). (C, D) At 14 days post-differentiation, PMSCs grown in muscle
differentiation media showed multi-nucleated skeletal muscle fiber formation (20X). 40X
magnification is shown in the bottom right corner. White arrows indicate multi-nucleated
muscle cells. (E-H) Cells grown in muscle differentiation media, showed less OCT4
(green-Alexa 488, λ-488 nm) and more MHC immunoreactivity (red-Alexa 568, λ-568
nm), when compared to PMSCs in 10% FBS at 14 days post-differentiation (10X).
Nuclei, were stained with Hoechst dye (blue, λ=340 nm). Experiment was performed in
triplicate from one placental tissue.
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Figure 2.2. PMSCs cultured under muscle differentiation conditions increased levels
of muscle markers (Pax3/7, MyoD, MyoG, and MHC) and decreased OCT4 and
SOX2 levels. Compared to PMSCs cultured under control conditions, (A) OCT4 was
decreased at 1 and 14 days under muscle differentiation conditions. (B) SOX2 levels
were decreased at each time point under muscle differentiation conditions. (C) Pax3/7
was increased at day 7 and decreased by day 14 under muscle differentiation conditions.
(D) MyoD, (E) MyoG, and (F) MHC were increased at each time point under muscle
differentiation conditions. Protein levels were quantified by densitometry and normalized
to β-Actin. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni‟s multiple comparison test was
performed to determine *P<0.05, **P<0.01, ***P<0.001 comparing control to muscle
differentiation conditions, or
treatment over time.
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Figure 2.3. PMSCs cultured under skeletal muscle differentiation conditions showed
a decreased frequency of cells with high ALDH-activity. Representative flow
cytometry dot plots showing the frequency of PMSC with high ALDH-activity with
Aldefluor and an inhibitor of ALDH (DEAB) or with ALDH alone when cultured under
control (10% FBS) or muscle differentiation conditions at (A) day 1, (B) day 3, (C) day
7, (D) and day 14. (E) Compared to PMSCs cultured under control conditions, PMSCs
cultured under differentiated conditions showed significantly decreased frequency of
cells with high ALDH-activity. Even under control culture conditions, PMSCs showed
diminished ALDH-activity over time. Data is presented as the mean ± SEM of 3
independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test was performed to determine ***P<0.001
comparing control to muscle differentiation conditions, or
same treatment over time.
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2.3.2 PMSCs Cultured under Muscle Differentiation Conditions Showed Higher
IGFBP-6 Expression, with Higher IGF-2 Secretion
PMSCs cultured under skeletal muscle differentiation conditions were investigated to
determine if they expressed IGFBP-6. Using immunocytochemistry, PMSCs cultured
under differentiation conditions showed high intracellular IGFBP-6 immunoreactivity
compared to PMSCs cultured under control conditions (Figure 2.4A, 2.4B, and S2.3).
Using immunoblotting at multiple time points, IGFBP-6 protein levels were increased in
PMSCs under differentiation conditions. Following day 2 of differentiation, IGFBP-6
levels gradually decreased in PMSCs cultured under differentiation conditions but
remained higher than time-matched controls (Figure 2.4C). Using ELISA detection in
PMSC conditioned media, both IGFBP-6 and IGF-2 secretion was increased at every
time point with muscle differentiation conditions compared to PMSCs cultured under
control conditions (10% FBS), confirming that developing muscle cells secrete IGFBP-6
and IGF-2 into the extracellular space (Figure 2.4D and 2.4E). Therefore, the synthesis of
IGFBP-6 and IGF-2 increased as the cells became more differentiated into skeletal
muscle.
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Figure 2.4. PMSCs cultured under skeletal muscle differentiation conditions showed
increased IGFBP-6 expression and secretion. (A, B) PMSCs cultured under muscle
differentiation conditions showed higher IGFBP-6 staining (red-Alexa, λ-568 nm) when
compared to PMSCs under control conditions (10% FBS) at 14 days post-differentiation.
Nuclei, were stained with Hoechst dye (blue, λ=340 nm). (C) IGFBP-6 protein levels in
PMSCs cultured under differentiation conditions were increased at each time point
compared to control conditions. Under muscle differentiation conditions, IGFBP-6 levels
peaked at 2 days post-differentiation and gradually decreased from day 3 to 14. Protein
levels were quantified by densitometry and normalized to β-Actin. (D) IGFBP-6 and (E)
IGF-2 secretion into the media was increased under muscle differentiation conditions
compared to control conditions. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, **P<0.01, ***P<0.001 comparing
control to muscle differentiation conditions, or #P<0.05, ##P<0.01, ###P<0.001 comparing
the same treatment over time.
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2.3.3 IGFBP-6 Affects Multipotency of the Developing Muscle Cells from PMSCs
before Muscle Commitment
To test the effects of extracellular IGFBP-6 on PMSC differentiation to muscle,
recombinant human IGFBP-6 was supplemented to the media. Addition of extracellular
IGFBP-6 into the culture media increased intracellular IGFBP-6 detection by western
blots, suggesting that recombinant human IGFBP-6 induced a positive feedback effect or
was taken up by the differentiating cells (Figure 2.5A). Furthermore, stimulation in
IGFBP-6 increased OCT4 and SOX2 levels (Figure 2.5B, and 2.5C). Interestingly,
IGFBP-6 supplementation also increased Pax3/7 levels suggesting enhanced PMSC
commitment towards the skeletal muscle lineage (Figure 2.5D). Finally, IGFBP-6
treatment increased the levels of muscle-specific markers, MyoD, MyoG, and MHC at
the earlier time points with a decline over time in the prolonged presence of increased
extracellular IGFBP-6 compared to un-supplemented muscle differentiation conditions
(Figure 2.5E, 2.5F, and 2.5G). Collectively, these data suggested that IGFBP-6 promoted
PMSC commitment to the muscle lineage as an immediate effect but maintained
pluripotency-associated markers and delayed muscle differentiation at later time points,
as seen with the decreased protein level of muscle differentiation markers.
Due to the fact that both potency and differentiation markers increased by IGFBP-6
treatment in a time-dependent manner, we tested the cells for ALDH-activity to
determine the frequency of PMSCs that maintained high ALDH progenitor phenotype.
Under muscle differentiation conditions, extracellular IGFBP-6 supplementation
increased ALDH-activity at day 1 (Figure 2.6A), day 3 (Figure 2.6B), and day 7 (Figure
2.6C), but not at day 14 (Figure 2.6D). After analysis of 3 independent samples from one
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placenta, increased retention of high ALDH progenitor cell frequency was consistently
observed after IGFBP-6 treatment (Figure 2.6E), suggesting that IGFBP-6 addition
prolonged primitive progenitor phenotype in PMSCs cultured under muscle
differentiation conditions. Further immunocytochemistry analyses at day 14, revealed
that compared to un-supplemented conditions, PMSCs treated with IGFBP-6 showed
more muscle compaction (Figure 2.7A, 2.7B, and S2.4A) with fewer cells per field
(Figure S2.4B). Furthermore, OCT4 and MHC immunoreactivity appeared equivalent
with or without IGFBP-6 supplementation (Figures 2.7C to 2.7F). ALDH-activity results
further suggested that IGFBP-6 treatment maintained PMSCs potency before PMSC
commitment to the muscle lineage. Collectively, these findings need to be further
investigated to confirm the identity of cells over -time.
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Figure 2.5. PMSCs treated with IGFBP-6 increased pluripotency-associated and
muscle differentiation markers. IGFBP-6, OCT4, SOX2, Pax3/7, MyoD, MyoG, and
MHC protein levels were quantified within PMSCs grown in muscle differentiation
media with or without IGFBP-6 (375 ng/mL) supplementation. (A) IGFBP-6 treatment
increased IGFBP-6 levels as compared to PMSCs grown in muscle differentiation media
only. IGFBP-6 treatment also increased pluripotency-associated markers (B) OCT4 and
(C) SOX2 levels. (D) IGFBP-6 treatment increased muscle lineage commitment marker
Pax3/7 at each time point. Muscle differentiation markers (E) MyoD, (F) MyoG, and (G)
MHC levels increased with IGFBP-6 treatment at early time points (1-3 days) but
showed reduced levels at later time points (7-14 days). Protein levels were quantified by
densitometry and normalized to β-Actin. Data is presented as the mean ± SEM of 3
independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test was performed to determine *P<0.05, **P<0.01,
***P<0.001 comparing treatments, or #P<0.05, ##P<0.01, ###P<0.001 comparing the same
treatment over time.
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Figure 2.6. IGFBP-6 treatment increased the frequency of PMSCs with high ALDHactivity. Representative flow cytometry dot plots with Aldefluor and an inhibitor
(DEAB) or with ALDH alone in PMSCs cultured under muscle differentiation conditions
with or without IGFBP-6 addition at (A) day1, (B) day 3, (C) day 7, and (D) day 14. (E)
At days 1, 3, and 7, PMSCs treated with IGFBP-6 showed increased frequency of cells
with high ALDH-activity. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, ***P<0.001.
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Figure 2.7. PMSCs treated with IGFBP-6 showed similar immunofluorescence for
OCT4 and MHC at 14 days under muscle differentiation conditions. Compared to
PMSCs cultured under muscle differentiation alone, (A, B) PMSCs treated with IGFBP-6
showed high cell compaction at day 14 (10X). (C-F) PMSCs were immunoreactive for
OCT4 (green-Alexa, λ-488 nm) and MHC (red-Alexa, λ-568 nm), with no change in
immunoreactivity with IGFBP-6 treatment. Nuclei were stained with Hoechst dye (blue,
λ=340 nm). Images are representative of 3 technical replicate.
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2.3.4 IGFBP-6 Knockdown Delayed PMSC Differentiation into Muscle Cells
To evaluate the effects of IGFBP-6 silencing on pluripotency-associated and muscle
differentiation markers in PMSCs, IGFBP-6 knockdown by siRNA was used during
muscle differentiation over 7 days. As predicted, PMSC expression of IGFBP-6 was
decreased for 1-2 days after IGFBP-6 knockdown compared to scrambled siRNA control.
However, IGFBP-6 levels were equivalent to scrambled controls by day 3. Readministration of IGFBP-6 siRNA at day 3 prolonged IGFBP-6 reduction, but IGFBP-6
returned to control levels by day 6 (Figure 2.8A), indicating that siRNA treatment
resulted in transient IGFBP-6 silencing. Alongside IGFBP-6 knockdown, we observed a
reduction in pluripotency-associated markers for OCT4 (Figure 2.8B) and SOX2 (Figure
2.8C), concomitant with reduced IGFBP-6 levels, suggesting that IGFBP-6 may be
important for maintain potency which needs to be further investigated. In contrast, levels
of the muscle commitment marker Pax3/7 were increased during IGFBP-6 knockdown at
day 1 and 2 but returned to control levels by day 3 (Figure 2.8D). Similarly, levels of the
muscle lineage differentiation markers MyoD, MyoG, and MHC were all decreased at
early time points after IGFBP-6 knockdown (Figures 2.8E to 2.8G). Increased protein
levels of muscle commitment marker and reduced levels of muscle differentiation
markers suggest that endogenous IGFBP-6 knockdown initiated PMSCs commitment to
the muscle lineage but delayed muscle differentiation. However, IGFBP-6 knockdown
did not change cell morphology when compared to the control at day 7 post-treatment
(Figure 2.9A and 2.9B) which needs to be further investigated.
On the other hand, IGFBP-6 knockdown decreased IGFBP-6 production and secretion as
IGFBP-6 levels were reduced in PMSC conditioned media at all-time points as measured
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by ELISA (Figure 2.9C). In addition, the frequency of cells with high ALDH-activity,
was decreased with IGFBP-6 knockdown compared to control (scrambled siRNA) at
days 1 and 3 (Figure 2.10).
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Figure 2.8. IGFBP-6 knockdown in PMSCs under muscle differentiation conditions
reduced muscle markers protein levels. PMSCs were treated with siRNAs against
IGFBP-6, or scrambled siRNA control every 3 days in muscle differentiation media. (A)
IGFBP-6 levels were significantly decreased at 1 and 2 days after siRNA treatment but
recovered to control levels at day 3. When IGFBP-6 siRNA was reintroduced at day 3,
there was a significant decrease for up to 5 days which returned to control levels at day 6.
IGFBP-6 siRNA treatment decreased (B) OCT4 and (C) SOX2 levels at the early time
points then returned to control levels at day 5. In contrast, muscle cell commitment
marker (D) Pax3/7 was increased at days 1 and 2 when IGFBP-6 was knocked-down.
Muscle differentiation markers: (E) MyoD, (F) MyoG, and (G) MHC levels were
decreased at early time points but recovered to control levels by day 5. Protein levels
were quantified by densitometry and normalized to β-Actin. Data is presented as the
mean ± SEM of 3 independent experiments from one preterm placenta. Two-way
ANOVA with Bonferroni‟s multiple comparison test was performed to determine
*P<0.05, **P<0.01, ***P<0.001 comparing siRNA treatments, or #P<0.05,
###

P<0.001 comparing the same treatment over time.

##

P<0.01,
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Figure 2.9. IGFBP-6 siRNA treatment maintained PMSCs cell morphology and
inhibited IGFBP-6 secretion. PMSC skeletal muscle morphology was maintained for 7
days under muscle lineage differentiation conditions with (A) scrambled siRNA or (B)
IGFBP-6 siRNA treatment. (C) IGFBP-6 secretion was decreased at each time point with
IGFBP-6 siRNA treatment that was applied every 3 days. Data is presented as the mean ±
SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test was performed to determine ***P<0.001.
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Figure 2.10. IGFBP-6 siRNA in PMSCs cultured under muscle differentiation
conditions decreased the frequency of cells with high ALDH-activity. Representative
flow cytometry dot plots with Aldefluor and an inhibitor of ALDH (DEAB) or with
ALDH alone of PMSCs treated with IGFBP-6 siRNA at (A) day 1, (B) day 3, and (C)
day 7 under muscle differentiation conditions. (D) PMSCs treated with IGFBP-6 siRNA
showed significantly reduced frequency of cells with high ALDH-activity. Data is
presented as the mean ± SEM of 3 independent experiments from one preterm placenta.
Two-way ANOVA with Bonferroni‟s multiple comparison test was performed to
determine ***P<0.001.
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2.4 DISCUSSION
Stem cell research has progressed in recent years and the promise of using stem cells in
tissue regeneration and cellular therapies is closer to becoming a reality in the clinical
field (22, 23). However, before they can be used reliably and safely in regenerative
medicine, it is essential to understand how factors within the stem cell microenvironment
influence lineage commitment and differentiation as stem cell fate is altered by the
culture conditions in vitro (24). In addition, most current cellular therapies utilize
multipotent stem cells already poised to generate a desired lineage of committed
progenitor cells by culturing them under specific differentiation conditions prior to
therapy. Congenital muscular dystrophies represent a potential genetic disorder that may
be amenable to cellular therapies due to accessibility and possible incorporation of new
functional skeletal muscle cells into diseased tissues after transplantation (25, 26).
Results from this study are the first to provide insight into how IGFBP-6 can be used to
modulate muscle lineage commitment and differentiation from readily-available PMSCs
in vitro.
The human placenta is usually discarded, but it represents a rich source of adult
mesenchymal stem cells for the development of regeneration therapies (2, 3, 27). Due to
early ontogeny, PMSCs demonstrate greater expansion capacity in vitro as compared to
mesenchymal stem cells isolated from adult bone marrow (1). They also demonstrate low
tumorigenicity (28) and high immunotolerance capacity to reduce the possibility of
triggering an immune response (29). Thus, placental stem cells could provide a readily
available source of MSCs for future clinical applications.
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The IGF family plays a central role in muscle development, differentiation, growth, and
regeneration (14-16, 30, 31). IGFBPs are the carriers for IGFs in the circulation (7),
protecting them from degradation (6, 32), and delivering them to specific tissues and thus
modulating the biological actions of IGFs. Also, IGFBPs increase the half-life of the IGF
peptides in the circulation and control their access to the IGF-1R, thus playing an
important role in IGF regulated cell metabolism, development, and growth. In recent
years, it has become apparent that the IGFBPs have functions independent of IGFs (8).
Several IGF-binding proteins have been shown to be important in myogenesis and are
expressed in developing muscle cells. Ren et al. reported that in C2C12 myoblast cells
and in primary skeletal muscle cells, IGFBP-5 acts in an IGF-dependent manner to
promote myogenesis by binding to IGF-2 and promoting its interaction with the IGF-1R
(33). Knockdown of IGFBP-5 impaired myogenic differentiation by reducing myogenin,
myosin heavy chain, and IGF-2 expression (33). In L6E9 skeletal myoblasts, IGFBP-4
and IGFBP-6 were accumulated during myogenesis, with IGFBP-4, not IGFBP-6,
inhibiting IGF-1 induced muscle differentiation (34). These findings suggested the
important role of IGFBPs in the differentiation of both primary cell lines of skeletal
muscle lineage. Our study is the first to demonstrate the role of IGFBP-6, which is
specific for the embryonic IGF, IGF-2, in muscle development using PMSCs.
The aim of this study was to characterize the effects of IGFBP-6 on early differentiation
stages before PMSCs commit to the muscle lineage. When PMSCs were cultured under
muscle differentiation conditions, they showed the capacity to differentiate into multinucleated fibers. The biological effects of IGFBP-6 on this differentiation process, as
determined by markers of multipotency (OCT4 and SOX2), muscle commitment
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(Pax3/7), and differentiation (MyoD, MyoG, and MHC) were significantly changed at
early time points. Thus, suggesting that IGFBP-6 induced muscle differentiation and
could potentially be used to guide skeletal muscle regeneration using stem cell therapy.
IGFBP-6 was highly expressed in developing muscle cells (35, 36), however, its role in
muscle development is unclear. Previous studies from our laboratory using human fetal
tissues have demonstrated that IGFBP-6 mRNA is expressed abundantly in the skeletal
muscle, heart and skin, and prevalent in the regions of active cellular division and
differentiation, suggesting that the protein is synthesized in these tissues and has
autocrine/paracrine actions in developing cells (37). In another study from our laboratory,
we reported that IGFBP-6 mRNA was expressed in low abundance in the chorionic villi
of placenta during the second and third trimesters (38), suggesting that this IGFBP-6 is
expressed in PMSCs and that the expression is increased only when PMSCs are induced
to differentiate into a specific lineage such as skeletal muscle.
The findings in this current study suggest that PMSCs in the developing myotome
express IGFBP-6 during differentiation, indicating that IGFBP-6 is an integral protein
during muscle development. In fact, as muscle differentiation progressed in vitro,
intracellular IGFBP-6 decreased gradually as seen with IGFBP-6 protein levels due to the
capacity to secrete IGFBP-6 into the culture medium. These results indicate that IGFBP6 may have both intracellular and extracellular effects on muscle development. Thus,
IGFBP-6 activities may switch from intracellular IGF-independent actions to more
paracrine IGF-dependent or IGF-independent actions as muscle differentiation occurs.
Interestingly, the addition of IGFBP-6 to the culture medium increased cellular IGFBP-6
(intracellular or cell-associated) with a concurrent increase in pluripotency-associated
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markers OCT4 and SOX2. The increase in intracellular IGFBP-6 suggests that IGFBP-6
was likely internalized or associated with the cell surface which needs to be further
investigated.
When extracellular IGFBP-6 was supplemented into PMSC cultured under muscle
differentiation conditions, the muscle commitment marker, Pax3/7 was increased at alltime points of the study, while muscle differentiation markers increased only at the
earliest time points. As differentiation progressed, IGFBP-6 treatment delayed myogenic
differentiation as demonstrated by decreased muscle differentiation markers MyoD,
MyoG and MHC. These findings together with the higher OCT4 and SOX2 levels
indicate that IGFBP-6 promotes the commitment of PMSCs towards the muscle lineage,
while the prolonged presence delays the muscle differentiation process. Therefore,
IGFBP-6 may be playing a dual role in both PMSC multipotency and differentiation
towards skeletal muscle, with greater impact before muscle commitment has occurred.
Moreover, increased IGFBP-6 in the MSC microenvironment is expected to reduce the
bioavailability of IGF-2 due to its high affinity for the peptide, confirmed by IGF-2
ELISA (Figure S2.5A). Thus, it is likely that increased IGF-2 secretion by differentiating
muscle cells will have a biologic impact on muscle development, which was further
investigated in chapter three.
Knockdown of IGFBP-6 using siRNA decreased both intracellular and secreted IGFBP6. This knockdown resulted in decreased OCT4 and SOX2 levels, suggesting that
IGFBP-6 enhances the multipotent progenitor cell phenotype in PMSCs. In contrast, the
early increase in Pax3/7 in response to IGFBP-6 silencing indicates an earlier
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commitment towards the myogenic lineage. Increased Pax3/7 may be correlated to the
presence of increased extracellular IGF-2 (Figure S2.5B). In contrast, the muscle
differentiation markers MyoD, MyoG, and MHC were all reduced after IGFBP-6
knockdown, suggesting IGFBP-6 is required for the muscle differentiation processes.
Therefore, IGFBP-6 loss leads to an early commitment towards the myogenic lineage but
delayed differentiation. However, there results needs to be further investigated using a
more stable knockdown of IGFBP-6 because IGFBP-6 siRNA was transient and the
IGFBP-6 levels returned to control. Moreover, the IGFBP-6 knockdown was performed
for 7 days and a longer time point (14 days) may provide additional information to help
delineate the results.
Overall, we have demonstrated that IGFBP-6 has both endogenous and exogenous
actions that can promote or inhibit PMSC multipotency or differentiation. Extracellular
IGFBP-6 facilitated muscle lineage commitment while a prolonged exposure inhibited
late stage differentiation. Therefore, endogenous IGFBP-6 may be required for
maintaining PMSC multipotency, delaying commitment, and enhancing late stage
differentiation. This could occur through different possible pathways in a time-dependent
manner that needs to be further investigated to confirm the mechanisms of IGFBP-6
effects on PMSCs muscle differentiation. IGFBP-6 addition before PMSCs commit to the
muscle lineage may cause IGFBP-6 to bind to another muscle protein and form a
complex to activate myogenesis. IGFBP-6 may bind to an inhibitor of myogenesis and
either prevent it from inhibiting muscle differentiation or enhance the inhibitors
functions. IGFBP-6 may be affecting myogenesis through IGF-1R and its downstream
signaling pathways (PI3K or MAPK) or independent of IGF binding.
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There is still a lot of work to be done to determine the mechanism for IGFBP-6 effects on
PMSCs myogenesis and to confirm the outcomes from this study as experiments were
performed from one preterm placental tissue (15 weeks) and increasing the sample
number to have biological replicates will help confirm the results and better clarify the
data.
In conclusion, PMSCs differentiate into skeletal muscle cells under appropriate niche
conditions, and this process is enhanced by the increase in extracellular IGFBP-6 and
delayed by silencing IGFBP-6 expression (Figure 2.11). The balance between
endogenous and exogenous levels of IGFBP-6 controls muscle differentiation, and since
IGFBP-6 has intracellular and extracellular effects, the response may occur dependent or
independent of IGFs (particularly IGF-2).
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Figure 2.11. Model of IGFBP-6 functions on PMSCs differentiation into skeletal
muscle. PMSCs under normal growth conditions (10% FBS) express high levels of
pluripotency-associated markers OCT4 and SOX2. As these cells commit towards the
skeletal muscle lineage, increased IGFBP-6 correlated with increased Pax3/7 that
decreased as differentiation markers (MyoG, MyoD, and MHC) were increased. Both
committed and differentiated muscle cells continued to express and secrete IGFBP-6. As
IGFBP-6 increased, there was an increase in multipotency markers, as well as, an earlier
commitment and differentiation towards the muscle lineage. Thus, IGFBP-6 was required
for maintaining multipotency and enhancing muscle commitment and differentiation.

87

2.5 REFERENCES
1.

Anker PS, et al. Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin
from Human Placenta. Stem Cells 2004; 22:1338-1345.

2.

Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human
Placenta-Derived Cells Have Mesenchymal Stem/Progenitor Cell Potential. Stem
Cells 2004; 22:649-658.

3.

Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, Qian H, Zhang X. Isolation of
mesenchymal stem cells from human placenta: comparison with human bone
marrow mesenchymal stem cells. Cell Biol Int 2006; 30:681-687.

4.

Buckingham M. Skeletal muscle progenitor cells and the role of pax genes. C. R.
Biologies 2007; 330:530-533.

5.

Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins:
biological actions. Endocr. Rev 1995; 16:3-34.

6.

Cohick WS, Clemmons DR. The insulin-like growth factors. Annu. Rev. Physiol
1993; 55:131-153.

7.

Shimasaki S, Ling N. Identification and molecular characterization of insulin-like
growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth
Factor Res 1991; 3:243-266.

8.

Bach LA, Headey SJ, Norton RS. IGF-binding proteins-the pieces are falling into
place. Trends Endocrinol. Metab 2005; 16: 228-234.

9.

Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, Rechler MM. Binding of
mutants of human insulin-like growth factor II to insulin-like growth factor
binding proteins 1-6. J. Biol. Chem 1993; 268:9246-9254.

10.

Bach LA. IGFBP-6 five years on; not so „forgotten‟?. Growth Hormone & IGF
Research 2005; 15:185-192.

11.

Bach LA, Fu P, Yang Z. Insulin-like growth factor-binding protein-6 and cancer.
Clinical Science 2013; 124:215-229.

12.

Janosi JB, Ramsland PA, Mott MR, Firth SM, Baxter RC, Delhanty PJ. The acidlabile subunit of the serum insulin-like growth factor-binding protein complexes
Structural determination by molecular modeling and electron microscopy. J. Biol.
Chem 1999; 274:23328-23332.

88

13.

Iosef C, Vilk G, Gkourasas T, Lee KJ, Chen B, Fu P, Bach LA, Lajoie G, Gupta
M B, Li SS, Han VK. Insulin-like growth factor binding protein 6 (IGFBP-6)
interacts with DNA-end binding protein Ku80 to regulate DNA repair and
apoptosis. J. Cell Sci 2010; 22:1033-1043.

14.

Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null
mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1
IGF receptor (Igf1r). Cell 1993; 75.1: 59-72.

15.

Powell-Braxton L, et al. IGF-I is required for normal embryonic growth in mice.
Genes Dev 1993; 7:2609-2617.

16.

Zanou N, Gailly P. Skeletal muscle hypertrophy and regeneration: interplay
between the myogenic regulatory factors (MRFs) and insulin-like growth factors
(IGFs) pathway. Cell. Mol. Life Sci. 2013; 70:4117-4130.

17.

Iosef C, Gkourasas T, Jia CY, Li SS, Han VK. A functional nuclear localization
signal in insulin-like growth factor binding protein-6 mediates its nuclear import.
Endocrinology 2008; 149: 1214-1226.

18.

Worton RG, McCulloch EA, Till JE 1969 Physical separation of hemopoietic
stem cells from cells forming colonies in culture. J Cell Physiol 74:171-182.

19.

Hess DA, et al. Functional characterization of highly purified human
hematopoietic repopulating cells isolated according to aldehyde dehydrogenase
activity. Blood 2004; 104(6):1648-1655.

20.

Capoccia BJ, et al. Revascularization of ischemic limbs by human bone marrow
cells purified by aldehyde dehydrogenase activity. Blood 2009; 113(21):53405351.

21.

Putman DM, Liu KY, Broughton HC, Bell GI, Hess DA. Umbilical cord bloodderived aldehyde dehydrogenase-expressing progenitor cells promote recovery
from acute ischemic injury. Stem Cells 2012; 30(10): 2248-2260.

22.

Mimeault M, Batra SK. Recent progress on tissue-resident adult stem cell biology
and their therapeutic implications. Stem Cell Rev 2008; 4(1):27-49.

23.

Andersson ER, Lendahl U. Regenerative medicine: a 2009 overview. J Intern
Med 2009; 266(4):303-10.

24.

Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M.

89

Characterization of the optimal culture conditions for clinical scale production of
human mesenchymal stem cells. Stem Cells 2006; 24:462-71.
25.

Péault B, et al. Stem and progenitor cells in skeletal muscle development,
maintenance, and therapy. Molecular Therapy 2007; 15(5): 867–877.

26.

Meregalli M, et al. Perspectives of stem cell therapy in Duchenne muscular
dystrophy. FEBS Journal 2012; 10:1111-12083.

27.

Parolini O et al. Concise review: isolation and characterization of cells from
human term placenta: outcome of the first international Workshop on Placenta
Derived Stem Cells. Stem Cells 2008; 26(2): 300-11.

28.

Koh, MB, Suck G. Cell therapy: promise fulfilled? Biologicals : journal of the
International Association of Biological Standardization, 2012; 40(3): p. 214-217.

29.

Ding DC, Shyu WC, Lin SZ, Mesenchymal stem cells. Cell Transplant, 2011;
20(1): p. 5-14.

30.

Musaro A, et al. Localized Igf-1 transgene expression sustains hypertrophy and
regeneration in senescent skeletal muscle. Nat. Genet. 2001; 27:195-200.

31.

Musaro A, Giacinti C, et al. Stem cell-mediated muscle regeneration is enhanced
by local isoform of insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA.
2004; 101:1206-1210.

32.

Grimberg A, Cohen P. Role of insulin-like growth factors and their binding
proteins in growth control and carcinogenesis. J. Cell Physiol 2000; 183:1-9.

33.

Ren H, Yin P, Duan C. IGFBP-5 regulates muscle cell differentiation by binding
to IGF-II and switching on the IGF-II auto-regulation loop. J. Cell Biol. 2008;
182 (5): 979-991.

34.

Silverman LA, Cheng ZQ, Hsiao D, Rosenthal SM. Skeletal muscle cell-derived
insulin-like growth factor (IGF) binding proteins inhibit IGF-I-induced
myogenesis in rat L6E9 cells. Endocrinology. 1995; 136(2):720-6.

35.

Putzer P, et al. Mouse insulin-like growth factor binding protein-6: expression,
purification,

characterization

and

histochemical

localization.

Mol.

Cell

Endocrinol 1998; 137:69-78.
36.

Raykha C, Crawford J, Gan BS, Fu P, Bach LA, O'Gorman DB. IGF-II and
IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease.

90

Biochimica et Biophysica Acta 2013; 1832:1511-1519.
37.

Delhanty PJ, Hill DJ, Shimasaki S, Han VK. Insulin-like growth factor binding
protein-4, -5 and -6 mRNAs in the human fetus: localization to sites of growth
and differentiation? Growth Regul. 1993; 3(1):8-11.

38.

Han VK, Bassett N, Walton J, Challis JR. The expression of insulin-like growth
factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and
membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J
Clin Endocrinol Metab, 1996. 81(7): p. 2680-2693.

91

Appendix 1
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Figure S2.1. IGFBP-6 levels in response to IGFBP-6 supplementation in PMSCs
under skeletal muscle differentiation conditions. (A) PMSCs cultured under muscle
differentiation conditions showed increased IGFBP-6 protein levels, using western blots,
in response to different doses of recombinant human IGFBP-6 protein supplementation
with 375 ng/mL and 450 ng/mL having the highest band intensity. (B) IGFBP-6 secretion
into the media was increased with the supplementation of recombinant human IGFBP-6
protein (375 ng/mL) that reduced by time and was lower compared to control at day 3.
Data is presented as the mean ± SEM of 3 independent experiments from one preterm
placenta (15 weeks). Two-way ANOVA with Bonferroni‟s multiple comparison test was
performed to determine ***P<0.001.
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Figure S2.2. PMSCs cultured under muscle differentiation conditions showed the
formation of multi-nucleated fibers and lower cell count compared to control. (A) At
14 days post-differentiation, PMSCs grown in muscle differentiation media showed
multi-nucleated skeletal muscle fiber formation (40X).Black arrows indicate the multinucleated muscle. (B, C) Cells grown in muscle differentiation media, showed less OCT4
(green-Alexa 488, λ-488 nm) when compared to PMSCs in 10% FBS at 14 days postdifferentiation (20X). Nuclei, were stained with Hoechst dye (blue, λ=340 nm). (D)
PMSCs under muscle differentiation conditions showed lower cell count per field
compared to control. Data is presented as the mean ± SEM of 15 different fields from 3
independent experiments from one preterm placenta. One-way ANOVA followed by a
Student‟s t-test, **P<0.01.
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Figure S2.3. PMSCs cultured under skeletal muscle differentiation conditions
showed increased IGFBP-6 expression. (A, B) PMSCs cultured under muscle
differentiation conditions showed higher IGFBP-6 staining (red-Alexa, λ-568 nm) when
compared to PMSCs under control conditions (10% FBS) at 14 days post-differentiation
(20X). Nuclei, were stained with Hoechst dye (blue, λ=340 nm). Images are
representative of 3 technical replicates.
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Figure S2.4. PMSCs under muscle differentiation conditions treated with IGFBP-6
showed more muscle compaction with lower cell count compared to cells under
muscle differentiation alone. Data is presented as the mean ± SEM of 15 different fields
from 3 independent experiments from one preterm placenta (15 weeks). One-way
ANOVA followed by a Student‟s t-test, **P<0.001.
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(A)

(B)

Figure S2.5: IGF-2 secretion in PMSCs treated with IGFBP-6 or IGFBP-6 siRNA
under muscle differentiation conditions. (A) IGF-2 levels secreted into the media were
significantly decreased at each time point after IGFBP-6 addition compared the control.
(B) After treatment with siRNA against IGFBP-6 compared to controls (scrambled
siRNA), IGF-2 levels increased at the first 48 hours with siRNA treatment applied every
3 days. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta (15 weeks). Two-way ANOVA with Bonferroni‟s multiple comparison
test was performed to determine *P<0.05, **P<0.001.
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CHAPTER THREE
Insulin-Like Growth Factor-2 and Insulin-Like Growth Factor Binding Protein-6
Promote the Differentiation of Placental Mesenchymal Stem Cells into Skeletal
Muscle
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3.1 INTRODUCTION
Insulin-like growth factor (IGF) system regulates cell growth, differentiation, migration,
and cell survival through the integration of several receptor-dependent signal
transduction pathways (1). The IGF family consists of two IGF ligands, IGF-1 and IGF2, three cell surface receptors, type-1, type-2 IGF receptors, and the insulin receptor, and
six IGF binding proteins (IGFBPs) (1). IGF-1 and IGF-2 are circulating peptides, which
bind IGF-1R, a ligand-activated receptor tyrosine kinase (1, 2). IGFBPs act as carriers for
IGFs in the circulation (3), protecting them from degradation (2, 4), and regulating the
biological actions of IGFs by delivering them to specific tissues. The IGF family plays an
important role in fetal and placental development by stimulating proliferation,
differentiation and survival of various types of placental cells (5). IGFs are vital in cell
growth, development, and cell-fate changes through several mitogen activation cascades
(6-9). The IGF family is also important in muscle development as IGFs maintain muscle
cell viability, promote hypertrophy, and stimulate differentiation in cultured myoblasts
(9). The importance of IGFs and the IGF-1R in skeletal muscle development was
determined using loss-of-function animal models. IGF-1R knockout mice die soon after
birth as functional respiratory muscle was deficient and pups were unable to breathe (10,
11). Furthermore, IGF-1 and IGF-2 were expressed by skeletal muscle cells during
muscle repair in response to injury and exercise (12, 13). IGFs are the only factors known
to promote both muscle cell proliferation and differentiation (13). In response to muscle
injury, adult skeletal muscle regenerates by expressing myogenic regulatory factors
(MRFs) (13). During myogenesis, committed muscle cells differentiate into the muscle
lineage by expressing muscle commitment markers, Pax3 and Pax7, which in turn up-
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regulate MyoD and myogenin (14). After commitment, myoblasts fuse together and form
multinucleated fibers that express myosin heavy chain (MHC) (14).
After muscle injury, IGF-1 enhanced regeneration while loss of IGF-1 activity using
neutralizing antibodies caused a reduction in the number of regenerating myofibers in
vivo (15). IGF-2 which up-regulates its own gene expression during myogenesis in a
positive feedback loop (12), is expressed abundantly in the developing skeletal muscle
and is the major growth factor for muscle growth, differentiation, and regeneration (12,
13). When IGF-2 is inhibited, myogenesis does not occur (16). In fact, IGF-2 is required
to allow continued recruitment of MyoD-associated proteins at the Myogenin promoter
(17). Moreover, in cultured myoblasts, IGFs stimulate terminal differentiation through an
autocrine pathway dependent on IGF-2 secretion (18).
IGFBPs also play a role in fetal and placental development as they are expressed during
different stages of development in time-specific and cell-specific manner. Although, loss
of function studies targeting single IGFBP genes have not yielded significant phenotypic
changes in the fetus or placenta, it is thought that these subtle changes in development are
possible biologic compensation by other IGF-binding proteins. IGFBP-6, a member of
the IGF binding protein family, is expressed abundantly in developing muscle cells and is
required for myogenesis (13). It is a unique peptide among the IGFBPs due to its higher
binding affinity to IGF-2 versus IGF-1 (~70 to 100 fold) (19-22). The most commonly
reported function of IGFBP-6 is the modulation of IGF-2 activity. IGFBP-6 binds IGF-2
in the circulation and prevents IGF-2 from binding to the cell surface receptors, and
modulates IGF-2 bioavailability in vitro and in vivo (23, 24). IGFBP-6 can also bind and
localize IGF-2 at the cell surface, enhancing IGF-2 actions by delivering IGF-2 to the
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IGF-1R (24). However, the mechanisms controlling the multiple actions of IGFBP-6
remain unclear. Previous studies in Chapter 3, showed that both extracellular and
intracellular IGFBP-6 were expressed in PMSCs during myogenesis. In this study, we
determined whether IGFBP-6 impact on PMSCs differentiation into skeletal muscle is
dependent or independent of IGF-1 and IGF-2 binding (particularly IGF-2).

3.2 MATERIALS AND METHODS

3.2.1 PMSC Isolation
PMSC isolation and experiments were conducted with the approval from the Health
Sciences Research Ethics Board of Western University (REB# 12154). Informed consent
was obtained from healthy women undergoing therapeutic termination of pregnancy, and
the PMSCs used in this study were isolated from one 15 week preterm placental tissue.
After surgery, chorionic villi were dissected, washed, and minced with surgical scissors
and forceps, and then subjected to enzymatic digestion with collagenase IV (369 IU/mg),
hyaluronidase (999 IU/mg) (Sigma-Aldrich, Oakville, ON), and DNase I (2,000 IU/mg)
(Hoffmann-LaRoche, Mississauga, ON) for 10 minutes at room temperature, followed by
0.05% trypsin (Gibco/Invitrogen, Mississauga, ON) for 5 minutes at room temperature.
The sample was then washed for 10 minutes with 10% FBS in DMEM/F12 medium and
the resulting single cell suspension was separated by density centrifugation over a Percoll
(Sigma-Aldrich, Oakville, ON) discontinuous gradient using a modified protocol by
Worton et al. (25).
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3.2.2 Cell Culture
Cells from Percoll gradient fractions #3 and #4 were plated on to T75 flasks, cultured,
and maintained using DMEM/F12 media supplemented with 15% FBS serum
(Gibco/Invitrogen, Mississauga, ON) and FGF-2 (50 ng/mL) (Sigma-Aldrich, Oakville,
ON) containing 100 U/mL Penicillin, 100 µg/mL Streptomycin, and 0.25 µg/mL
Amphotericin-B. The non-adherent cells were discarded at the time of media change,
which was performed every 72 hours. The adherent cells were cultured until they reach
90% confluence. Cells were then passaged 1:2 approximately once per week using 0.05%
Trypsin for 10 min at 37°C for 3 passages. Passaged cells were stored at -80°C in 1 mL
of freezing media (30% FBS and 10% DMSO in DMEM/F12 media). When needed,
vials were thawed and cells were resuspended in normal culture media (25 ng/mL FGF-2
and 15% FBS in DMEM/F12).

3.2.3 Muscle Differentiation and IGF treatment
Cells were plated in muscle growth media (fetal bovine serum 0.05 mL/mL, fetuin 50
µg/mL, epidermal growth factor 10 ng/mL, basic fibroblast growth factor 1 ng/mL,
insulin 10 µg/mL, and dexamethasone 0.4 µg/mL) for 48 hours before changing to the
skeletal muscle differentiation media, which is a proprietary serum-free medium
containing 10 µg/mL insulin (PromoCell, Heidelberg, Germany) for 14 days with or
without 100 ng/mL of either IGF-1 or IGF-2 (Cell Signaling Technology, Danvers, MA).
IGFs were added every 3 days at the time of media change. Cells were grown in six well
plates in a standard tissue culture incubator at 37°C in 5% CO2.
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3.2.4 Down-Regulation of IGF-2 Expression by siRNA
To silence endogenous IGF-2 expression in PMSCs, siRNA against IGF-2 (Santa Cruz
Biotechnology, Dallas, TX) was used. 8 μL of Lipofectamine (Invitrogen, Mississauga,
ON) with either 8 μL of scrambled or IGF-2 siRNA was added to 100 μL of DMEM/F12
media (Invitrogen, Mississauga, ON) for 40 minutes at room temperature. The siRNA
solution was added to 60% confluent cells and incubated for 5 hours at 37ºC. Muscle
growth media (1.5 mL) was added for 48 hours and subsequently replaced with 2 mL of
muscle differentiation media (PromoCell, Heidelberg, Germany). New siRNA was added
every 3 days during the change of media for 14 days.

3.2.5 IGFBP-6
Recombinant human IGFBP-6 (PROSPEC, East Brunswick, NJ) was added to the media
(375 ng/mL) every 3 days at the time of media change. The IGFBP-6 concentration and
time of supplementation was determined as shown in Chapter 2 (Figure S2.1).

3.2.6 Cell Lysate Preparation
Following PMSC treatments, cells were washed with DPBS (Gibco/Invitrogen,
Mississauga, ON) and 200 μL of (1x) cell lysis buffer (Cell Signaling Technologies,
Burlington, ON) mixed with protease and phosphatase inhibitors (1:100) were added to
the cells. Cells were detached using a cell scraper and the lysate was sonicated for 15
seconds. Finally, samples were centrifuged for 15 min at 14,000 rpm at 4°C, and the
supernatant was collected.
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3.2.7 Immunoblotting
Cell lysates containing 20 µg of protein were added to 6x SDS gel loading buffer (1% βmercaptoethanol, 1% SDS, 30% glycerol, 0.0012% bromophenol blue, Tris HCl 0.28 M,
pH 6.8). Samples were boiled for 5 minutes at 95oC, then placed on ice for 3 minutes,
and centrifuged at 3,000 rpm for 20 seconds before loading. Samples were resolved by
molecular weight using 10% SDS polyacrylamide gels transferred onto poly-vinyl-denefluoride (PVDF) membranes (Bio-Rad, Hercules, CA) using a Trans-Blot Turbo (BioRad, Hercules, CA) with an optimized protocol depending on protein size. Membranes
were blocked with 5% non-fat-dry milk, gently shaking for 1 hour at room temperature in
Tris-HCl buffer saline pH 8.0 with 0.1% Tween-20 (TBS-T). Blots were then washed
with TBS-T (3 times for 10 minutes) followed by incubation at 4°C overnight with
specific primary antibodies in 5% BSA or 5% non-fat-dry milk in TBS-T following the
manufacturer‟s protocol. To detect stem cell-associated potency markers, antibodies for
OCT4 (N-19: sc-8628) (Santa Cruz Biotechnology, Dallas, TX), SOX2 (2683-1)
(Epitomics, Burlington, ON), and Nanog (3369-1) (Epitomics, Burlington, ON, CAN)
were used. To detect markers of muscle differentiation, Pax3/7 (E-10: sc-365613), MyoD
(M-318: sc-760), Myogenin (F5D: sc-12732), and Myosin heavy chain (H-300: sc20641) (Santa Cruz Biotechnology, Dallas, TX) were used. To detect IGFBP-6, antibody
H-70: sc-13094 (Santa Cruz Biotechnology, Dallas, TX) was used. To detect IGF-2,
antibody H-103: sc-5622 (Santa Cruz Biotechnology, Dallas, TX) was used. For loading
control, pan-Actin Ab-5 (Thermo Fisher Scientific, Fremont, CA) was used.
Then membranes were washed and incubated for 1 hour at room temperature with the
corresponding secondary HRP-conjugated antibody. The secondary antibodies used were
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HRP-conjugated goat anti-rabbit (#170-6515) or anti-mouse (#170-6516) (Bio-Rad,
Hercules, CA) or donkey anti-goat antibody (Santa Cruz Biotechnology, Dallas, TX).
Resolved protein bands were detected using chemiluminescence and images were taken
using the VersaDoc Imager (Bio-Rad, Hercules, CA). Western blots were performed in
triplicate.

3.2.8 Immunocytochemistry
PMSCs were grown on glass cover slips (80-90% confluence) for 14 days, stained with
primary antibodies (1:100), and incubated at 4°C overnight. To detect stem cellassociated potency markers, OCT4 antibody (N-19: sc-8628) (Santa Cruz Biotechnology,
Dallas, TX) was used. To detect markers of muscle differentiation, Pax3/7 (E-10: sc365613), MyoD (M-318: sc-760), and Myosin heavy chain (H-300: sc-20641) (Santa
Cruz Biotechnology, Dallas, TX) were used. To detect IGFBP-6, antibody H-70: sc13094 (Santa Cruz Biotechnology, Dallas, TX) was used. Primary antibodies were
washed using 0.1% Tween-20 in PBS (3 times for 5 minutes); cells were then incubated
in the dark with the corresponding secondary AlexaFlour conjugated antibody (1:200).
The secondary antibodies used were green-Alexa 488 or red-Alexa 568 (Invitrogen,
Mississauga, ON). The secondary antibody was washed with 0.1% Tween-20 in PBS,
and the nuclear stain (Hoechst dye) was added for 7 minutes and then rinsed. The cover
slips were mounted and images were taken using a confocal microscope (Zeiss,
Germany). Each antibody was in triplicates.
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3.2.9 Quantification of IGFBP-6 and IGF-2 Secretion by Enzyme-Linked
Immunosorbent Assay (ELISA)
Human IGFBP-6 (RayBiotech®, Burlington, ON) and IGF-2 (ALPCO, Salem, NH)
ELISA kits were used to measure the amount of IGFBP-6 and IGF-2 secreted into PMSC
conditioned media for 14 days. Standards and samples were loaded into the wells (in
triplicate) and the immobilized antibody bound IGFBP-6 or IGF-2 present in the sample.
The wells were washed and biotinylated anti-human antibody was added. After washing,
HRP-conjugated streptavidin was added; then a TMB substrate solution was used to
develop a blue color in proportion to the amount of IGFBP-6 or IGF-2 bound. The Stop
Solution changes color from blue to yellow, and the intensity was measured at 450 nm
using Multiskan Ascent plate reader and analysis software.

3.2.10 Aldehyde Dehydrogenase (ALDH) Activity
ALDH-activity, a conserved progenitor cell function, was assessed by flow cytometry for
14 days. Using the AldefluorTM assay (Stem Cell Technologies, Vancouver, BC), as per
the manufacturer‟s instructions. Briefly, 5 μL of activated Aldefluor reagent was added to
1 mL of cell suspension and incubated for 45 minutes at 37°C. Cells were washed and
resuspended in 500 μL of ice-cold Aldefluor assay buffer and ALDH-activity was
measured using flow cytometry. As a negative control, AldefluorTM DEAB reagent was
used. Samples were run in triplicate.

3.2.11 Statistical Analysis
All experiments were performed in triplicate from one 15 week placental tissue (technical
replicates). GraphPad Prism Software 5.0 was used to generate all graphs and analyses. A
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two-way ANOVA followed by a Bonferroni‟s multiple comparison test or a one-way
ANOVA followed by a Student‟s t-test was used to calculate significant differences when
p<0.05. Graphic representation values are presented as mean ± SEM (shown as variance
bars).

3.3 RESULTS

3.3.1 IGF-1 Affects PMSC Multipotency and Differentiation into Skeletal Muscle
To test the effects of exogenous IGF-1 on PMSC multipotency and differentiation to
muscle cells, IGF-1 was supplemented to muscle differentiation media (100 ng/mL)
every third day for up to 14 days. Immunocytochemistry analyses at day 14 revealed that
PMSCs treated with IGF-1 showed qualitatively increased Pax3/7, decreased MyoD, and
no change in OCT4 and MHC immunoreactivity (Figure 3.1). Moreover, IGF-1 treatment
increased the total number of cells per field compared to un-supplemented controls
(Figure S3.1) suggesting the IGF-1 stimulated proliferation which needs to be further
investigated.
Western blots were used to determine the protein levels of potency and muscle
differentiation markers. Pluripotency-associated marker OCT4 levels were not changed
by IGF-1 supplementation (Figure 3.2A), while both SOX2 (Figure 3.2B) and Nanog
(Figure 3.2C) levels were reduced at early time points compared to un-supplemented
muscle differentiation conditions. In contrast, IGF-1 supplementation increased Pax3/7
levels at 7 and 14 days suggesting PMSCs‟ commitment to the muscle lineage (Figure
3.2D). Finally, IGF-1 supplementation decreased the levels of muscle-specific
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differentiation marker, MyoD, at day 14 (Figure 3.2E), but did not change MyoG and
MHC levels (Figures 3.2F and 3.2G), compared to PMSCs cultured under unsupplemented muscle differentiation conditions.
ALDH-activity of PMSCs was determined for the frequency of PMSCs with conserved
phenotype of early progenitor cells (26-28). Under muscle differentiation conditions,
IGF-1 supplementation increased the frequency of cells with high ALDH-activity at alltime points compared to PMSCs under muscle differentiation alone (Figures 3.3A to
3.3D) suggesting that extracellular IGF-1 prolonged progenitor cell phenotype in PMSCs
under muscle differentiation conditions.

3.3.2 IGF-2 Affects PMSCs Multipotency and Differentiation into Skeletal Muscle
The impact of IGF-2 in PMSC multipotency and differentiation into skeletal muscle was
investigated by adding IGF-2 (100 ng/mL) to the muscle differentiation media. Using
immunocytochemistry, PMSCs cultured under muscle differentiation conditions
supplemented with IGF-2 showed no change in OCT4, Pax3/7, and MyoD
immunoreactivity (IR) (Figure 3.1). In contrast, muscle differentiation marker MHC
immunoreactivity (IR) was increased (Figure 3.1) at 14 days after IGF-2 treatment
compared to untreated controls, with fewer cells per field (Figure S3.1) suggesting that
IGF-2 enhanced the terminal muscle differentiation process.
Using western blots, we demonstrated that IGF-2 supplementation also increased the
protein levels of pluripotency-associated marker OCT4 at days 3, 7, and 14 compared to
PMSCs cultured in muscle differentiation media alone (Figure 3.2A), whereas other
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pluripotency-associated markers SOX2 (Figure 3.2B) and Nanog (Figure 3.2C) were
decreased. In contrast, IGF-2 supplementation increased the protein levels of the muscle
lineage commitment marker Pax3/7 and the muscle differentiation markers MyoD,
MyoG, and MHC levels compared to untreated controls (Figures 3.2D to 3.2G).
Moreover, IGF-2 supplementation of PMSCs under muscle differentiation conditions
decreased the frequency of cells with high ALDH-activity compared to PMSCs under
untreated muscle differentiation condition at all time points (Figure 3.3A to 3.3D),
suggesting that IGF-2 promoted the differentiation of PMSCs into skeletal muscle.
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Figure 3.1. PMSCs treated with IGF-2 showed qualitatively increased MHC
immunoreactivity (IR) at 14 days. Compared to PMSCs cultured under muscle
differentiation alone, PMSCs treated with IGF-1 or IGF-2 showed similar OCT4
immunoreactivity (red-Alexa, λ-568 nm). However, IGF-1 supplementation increased
Pax3/7 IR (green-Alexa, λ-488 nm), decreased MyoD IR, with no change in MHC IR
(red-Alexa, λ-568 nm). In contrast, IGF-2 treatment did not alter Pax3/7 IR (green-Alexa,
λ-488 nm) or MyoD IR, but increased MHC IR (red-Alexa, λ-568 nm). Nuclei, stained
with Hoechst dye (blue, λ=340 nm). Immunocytochemistry was performed in triplicate
with each antibody.
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Figure 3.2. IGF-1 and IGF-2 supplementation differently affected levels of
pluripotency-associated and muscle differentiation markers in PMSC. (A) IGF-1
treatment had no effect on OCT4 levels, while IGF-2 treatment increased OCT4 levels at
3, 7, and 14 days compared to muscle differentiation alone. (B) SOX2 and (C) Nanog
levels were decreased after IGF-1 treatment at early time points only, whereas IGF-2
treatment decreased SOX2 levels until day 7 and at all-time points for Nanog. (D) Pax3/7
levels were increased at 7 and 14 days and did not decrease after IGF-1 treatment, while
IGF-2 treatment increased Pax3/7 levels at all-time points but decreasing with time. (E)
MyoD, (F) MyoG, and (G) MHC protein levels did not change with IGF-1
supplementation, except for a decrease in MyoD levels at day 14. In contrast, IGF-2
treatment increased muscle differentiation marker levels at all-time points. Protein levels
were quantified by densitometry and normalized to β-Actin. Data is presented as the
mean ± SEM of 3 independent experiments from one preterm placenta. Two-way
ANOVA with Bonferroni‟s multiple comparison test was performed to determine
*P<0.05, **P<0.01, ***P<0.001 comparing control to muscle differentiation conditions,
or ###P<0.001 comparing the same treatment over time.
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Figure 3.3. PMSCs cultured under skeletal muscle differentiation conditions treated
with IGF-1 showed an increased frequency of cells with high ALDH-activity, while
cells treated with IGF-2 showed a decreased frequency. Representative flow
cytometry dot plots showing the frequency of PMSC with high ALDH-activity when
cultured under muscle differentiation conditions with or without either IGF-1 or IGF-2 at
(A) day 1, (B) day 3 , (C) day 7 , and (D) day 14. DEAB treated controls were used to
establish the ALDH gate (data not shown). (E) Compared to PMSCs under muscle
differentiation conditions, cells treated with IGF-1 showed increased frequency of cells
with high ALDH-activity, while cells treated with IGF-2 showed decreased frequency of
cells with high ALDH-activity. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, ***P<0.001.
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3.3.3 Extracellular IGFs Altered IGFBP-6 Levels
Using immunocytochemistry performed at day 14, IGF-1 treatment decreased IGFBP-6
immunoreactivity; whereas IGF-2 increased IGFBP-6 immunoreactivity in PMSCs
treated under muscle differentiation conditions (Figure 3.4A). Using western blots, we
showed increased IGFBP-6 levels with IGF-1 treatment at early time points, which
coincided with delayed muscle commitment as indicated previously by higher Pax3/7
levels (Figure 3.1D). In contrast, IGF-2 did not increase IGFBP-6 levels until day 14
compared to PMSCs under muscle differentiation only (Figure 3.4B). When compared to
PMSCs treated with IGF-1, IGF-2 treatment increased IGFBP-6 levels at 7 and 14 days
(Figure 3.4B) suggesting that IGF-2 treatment stimulated IGFBP-6 synthesis after
PMSCs commitment to the muscle lineage, whereas IGF-1 effect on IGFBP-6 synthesis
occurred before PMSCs commitment to muscle.
To investigate the effects of IGF-1 and IGF-2 on IGFBP-6 secretion into conditioned
media under muscle differentiation conditions, IGFBP-6 concentration in the PMSC
media was measured using ELISA. With IGF-1 treatment, IGFBP-6 concentration was
increased at early time points (day 1 and 3) and decreased at later time points (days 7 and
14) compared to control PMSCs under muscle differentiation conditions (Figure 3.4C).
In contrast, IGF-2 treatment increased IGFBP-6 secretion throughout differentiation until
day 14 (Figure 3.4C). Therefore, both IGFs increased IGFBP-6 synthesis by PMSCs
under muscle differentiation conditions with the effect of IGF-1 short lived and IGF-2 for
a long duration.
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Figure 3.4. IGFBP-6 expression is altered by IGF-1 and IGF-2 treatment in PMSCs
cultured under skeletal muscle differentiation conditions. (A) 14 days postdifferentiation, PMSCs grown in muscle differentiation media were immunoreactive for
IGFBP-6 (red-Alexa, λ-568 nm). IGF-1 decreased IGFBP-6 immunoreactivity and IGF-2
increased IGFBP-6 IR (nuclei stained with Hoechst dye, blue, λ=340 nm). (B) IGFBP-6
levels were increased by IGF-1 treatment at days 1 and 3 compared to PMSCs under
muscle differentiation alone, however they were reduced at days 7 and 14. IGF-2
treatment did not change IGFBP-6 levels until day 14 when they were increased
compared to controls. IGFBP-6 levels were quantified by densitometry and normalized to
β-Actin. (C) IGFBP-6 secretion into conditioned media was increased with both IGF-1
(day 1 and 3) and IGF-2 (day 1 to 7) compared to controls. However, secreted IGFBP-6
levels were significantly decreased at 7 and 14 days with IGF-1 treatment; and remained
increased with IGF-2 treatment. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, **=P<0.01, ***P<0.001 compared
to control (PMSCs under muscle differentiation), or #P<0.05,
between IGF-1 or IGF-2 treatments.

###

P<0.001 comparing
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3.3.4 Extracellular IGFBP-6 Maintains Muscle Differentiation by PMSCs in the
Absence of IGF-2
To evaluate the role of endogenous IGF-2 on PMSCs differentiation into skeletal muscle,
IGF-2 mRNA was silenced using siRNA every 3 days for up to 14 days. PMSCs with
IGF-2 knockdown showed lower muscle compaction compared to control (scrambled
siRNA) at day 14 (Figure 3.5A, 3.5B and S3.2). The addition of IGFBP-6 together with
IGF-2 siRNA permitted PMSCs compact muscle morphology at 14 days (Figure 3.5B
and 3.5C). As expected, IGF-2 levels were decreased by IGF-2 knockdown compared to
scrambled siRNA control. However, IGF-2 protein levels were equivalent to control
levels at day 14 although IGF-2 siRNA was administered every 3 days (Figure 3.5D)
indicating that siRNA-treatment was transient. Furthermore, IGF-2 levels remained
significantly low at all of the time points by the addition of IGFBP-6 with IGF-2
knockdown and did not return to control levels (Figure 3.5D), suggesting an interaction
between IGF-2 and IGFBP-6.
After IGF-2 knockdown, IGFBP-6 levels were increased until day 3 compared to
scrambled siRNA control (Figure 3.5E), suggesting greater availability of IGFBP-6
demonstrated by an increase in secreted IGFBP-6 (Figure S3.3). As expected, IGFBP-6
protein levels were increased at each time point during IGF-2 siRNA treatment alongside
extracellular IGFBP-6 supplementation compared to controls (Figure 3.5E).
Concurrent with IGF-2 knockdown, we observed a decrease in pluripotency-associated
marker OCT4 levels until day 3 with an increase at day 14 compared to scrambled
siRNA control (Figure 3.6A). In contrast, SOX2 levels did not change (Figure 3.6B).
Furthermore, the addition of IGFBP-6 with IGF-2 knockdown reduced both OCT4
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(Figure 3.6A) and SOX2 (Figure 3.6B) levels. The protein levels of muscle lineage
differentiation markers MyoD (Figure 3.6C) and MHC (Figure 3.6D) were decreased
significantly after IGF-2 knockdown indicating a critical role for IGF-2 in PMSC
differentiation into skeletal muscle. In contrast, IGFBP-6 supplementation alongside
IGF-2 knockdown significantly increased MyoD and MHC levels at 7 and 14 days
compared to siRNA scrambled control or IGF-2 knockdown alone (Figure 3.6C and
3.6D).
Knockdown of IGF-2 expression in PMSCs significantly decreased the frequency of cells
with high ALDH-activity compared to control (scrambled siRNA) at day 1 (Figure 3.7).
In contrast, the addition of IGFBP-6 together with IGF-2 knockdown further decreased
the frequency of cells with high ALDH-activity at all-time points compared to siRNA
scrambled control or IGF-2 siRNA treatment (Figure 3.7) Collectively, these data suggest
that IGFBP-6 reduced progenitor cell phenotype under muscle differentiation conditions
and maintained the differentiation of PMSCs towards skeletal muscle in the absence of
IGF-2.
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Figure 3.5. IGF-2 knockdown with siRNA inhibited PMSCs differentiation into
skeletal muscle and adding extracellular IGFBP-6 with the treatment helped rescue
muscle compaction. (A) Compared to PMSCs under muscle lineage differentiation
conditions with siRNA scrambled control, (B) PMSCs under muscle differentiation
conditions treated with IGF-2 siRNA showed less skeletal muscle compaction at 14 days
(10X). (C) Extracellular IGFBP-6 supplementation with IGF-2 knockdown enhanced the
PMSCs muscle compaction at 14 days compared to IGF-2 siRNA. The white arrows
indicate muscle compaction. (D) IGF-2 levels by PMSCs treated with IGF-2 siRNA
under differentiation conditions were reduced and returned to control levels by day 14,
while adding IGFBP-6 with IGF-2 knockdown maintained lower IGF-2 levels. (E)
IGFBP-6 protein levels increased until day 3 with IGF-2 knockdown compared to siRNA
scrambled control. IGFBP-6 addition with IGF-2 knockdown increased IGFBP-6 protein
levels at each time point. Protein levels were quantified by densitometry and normalized
to β-Actin. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni‟s multiple comparison test was
performed to determine *P<0.05, **=P<0.01, ***P<0.001 compared to scrambled
siRNA control, or #P<0.05, ###P<0.001 compared to IGF-2 siRNA.
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Figure 3.6. IGF-2 knockdown decreased muscle differentiation markers, while
adding IGFBP-6 partially increased the markers. (A) OCT4 levels were reduced with
IGF-2 knockdown until day 3 and increased at day 14. Adding IGFBP-6 alongside IGF-2
siRNA reduced OCT4 protein levels at all-time points compared to siRNA scrambled
control. In contrast, (B) SOX2 levels did not change with IGF-2 knockdown. But when
IGFBP-6 was added with IGF-2 silencing, the levels were reduced from 1-3 days
compared to control and IGF-2 knockdown. Protein levels of muscle differentiation
markers: (C) MyoD and (D) MHC decreased with IGF-2 siRNA and IGFBP-6
supplementation increased the levels. Protein levels were quantified by densitometry and
normalized to β-Actin. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, **P<0.01, ***P<0.001 compared
to scrambled siRNA control, or #P<0.05, ###P<0.001 compared to IGF-2 siRNA.
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Figure 3.7. IGF-2 knockdown and extracellular IGFBP-6 addition in PMSCs under
muscle differentiation conditions decreased the frequency of cells with high ALDHactivity. Representative flow cytometry dot plots showing the frequency of PMSCs with
high ALDH-activity when cultured under muscle differentiation conditions with or
without either IGF-2 siRNA or IGF-2 siRNA and extracellular IGFBP-6 at (A) day 1, (B)
day 3 , (C) day 7 , and (D) day 14. DEAB treated controls were used to establish the
ALDH gate (data not shown). (E) Compared to PMSCs under muscle differentiation
conditions (siRNA scrambled control), cells treated with IGF-2 siRNA showed decreased
frequency of cells with high ALDH-activity at day 1, while adding extracellular IGFP-6
with IGF-2 siRNA showed decreased frequency of cells with high ALDH-activity at each
time point. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni‟s multiple comparison test was
performed to determine **=P<0.01, ***P<0.001 compared to scrambled siRNA control,
or ###P<0.001 compared to IGF-2 siRNA.
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3.4 DISCUSSION
It is believed that if stem cells are to be used successfully in cell-based therapies for
specific diseases, the cells must be induced to differentiate towards a progenitor cell of a
desired lineage (e.g. skeletal muscle for muscular dystrophy) (29) prior to therapy. In
addition, adequate cell numbers will be needed for effective therapy. Human placenta,
which is usually discarded, is a source of adult mesenchymal stem cells with functional
capacity similar to bone marrow (30-33). PMSCs also demonstrate low tumorigenicity
with higher immunotolerance after transplantation, making them an ideal cell type for
tissue regeneration therapies (34-35).
The IGF system is important for muscle development, growth, regeneration, and
differentiation (10, 11, 13, 36, 37). IGF-2 plays an important role during C2C12
differentiation and is considered the main myogenic factor in myoblast cells (38). In C3H
10T1/2 fibroblasts converted by MyoD transfection to myoblasts, there was an increase
in the mRNA expression and protein levels of IGF-2 during the differentiation stage (16).
Taken together, these findings show the important role of the IGF family in muscle cell
differentiation.
IGF-binding proteins act as carriers for IGF-1 and IGF-2 in the circulation, facilitating
ligand delivery to specific tissues and controlling access to the IGF receptors (2, 3, 39).
Also, IGFBPs are expressed by many cell types, including skeletal muscle, and have been
demonstrated to have functions dependent and independent of IGF binding (4). For
example, IGFBPs are expressed within developing muscle cells and are important in
myogenesis (39, 40). In osteoblasts, IGFBP-6 has been shown to modulate cell growth by
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reducing the bioavailability of IGF-2 in the bone microenvironment (41). When L6E9
cells (a myoblast cell line used to study late myogenesis) are stimulated with IGF-1, these
cells initiated an initial proliferative response. During this time of rapid cell division the
myogenic regulatory factors were inhibited. Approximately 30 hours later, there was a
stimulation of myogenin expression (42). In mouse C2C12 cells and C2 satellite cell line,
there was a greater IGF-2 mRNA than IGF-1; 2000-folds to 20 folds respectively (12, 19,
43). This study is the first to show the effects of IGF-1, IGF-2, in combination with
IGFBP-6 on human PMSCs differentiation into skeletal muscle in vitro.
The aim of this study was to characterize the effects of IGFs on the differentiation of
PMSCs into skeletal muscle and to delineate their interactions with IGFBP-6. From our
data, we showed that IGF-1 can promote an early increase in IGFBP-6 expression before
PMSCs commit to the muscle lineage, a requirement that delayed muscle lineage
commitment. This was confirmed by the increased levels of muscle commitment marker,
Pax3/7, and decreased muscle differentiation marker (MyoD) after IGF-1 treatment. On
the other hand, IGF-2 treatment increased both IGFBP-6 and OCT4 levels. These results
are in agreement with previous studies in Chapter two, showing IGFBP-6 positive effects
on OCT4 levels. Also, the muscle differentiation markers (MyoD, MyoG, and MHC)
were increased at later time points with IGF-2 treatment, confirming that IGF-2 enhanced
PMSCs muscle differentiation, unlike IGF-1 (Figure 3.8). Increased OCT4 levels
occurred alongside a decrease in SOX2 and Nanog levels which is expected in a
mesodermal differentiation (44); OCT4 is needed for differentiation as it supports downregulating pluripotency, and when deficient, cells are not able to differentiate (45).
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In L6A1 myoblasts, IGFBP-6 inhibited muscle differentiation stimulated by IGF-2 but
not IGF-1 (46). In contrast, IGFBP-6 was required for PMSCs differentiation into
skeletal muscle and modulated both multipotency and muscle markers levels, as well as
IGF-2 secretion (Chapter Two). Therefore, we focused on the role of IGFBP-6 on IGF-2
in PMSCs under muscle differentiation conditions.
When IGF-2 was knocked down using siRNA, myogenesis was inhibited, and adding
IGFBP-6 helped recover the muscle differentiation process; supported by muscle
morphology and differentiation markers. Moreover, IGFBP-6 expression has been
previously associated with non-proliferative states and inhibition of IGF-2 dependent
tumor cell growth in rhabdomyosarcoma, neuroblastoma, and colon cancer (47). More
specifically, neuroblastoma cells undergo a decrease in both cell proliferation and
tumorigenic potency as a result of exogenous IGFBP-6 expression; as IGFBP-6
sequesters IGF-2 preventing a mitogenic response in tumor cells (48, 49). These results
are in agreement with our findings, as IGF-2 protein levels were reduced with IGFBP-6
extracellular addition and IGFBP-6 secretion into the media was higher after IGF-2
knockdown.
Previous studies in C2C12 cells showed that as muscle differentiation progressed, IGF-2
stimulated its own expression and inhibited IGF-1 expression in a time- and dosedependent manner (12). In our study, there was a decrease in the amount of secreted IGF2 to the media after IGF-1 treatment in PMSCs under muscle differentiation conditions;
indicating an intricate balance between IGF-1 and IGF-2 expression exists in the niche
during myogenesis from PMSCs (Figure S3.4).
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Placenta development is dependent on the IGF system, including IGF-1 and IGF-2 (50).
The importance of IGFs in the human placenta is well defined in mediating growth and
differentiation of the different cells of the chorionic villi (5, 51). In the human placenta,
IGF-2 mRNA is expressed in the villous mesenchymal core, where PMSCs reside (50).
IGF-2 also plays a role in the placenta at the early gestation, whereas IGF-1 is associated
in later gestation (52). In PMSCs, results from this study, showed that IGF-1 and IGF-2
had different effects on PMSCs differentiation into skeletal muscle in a time-dependent
manner. The role of IGF1 and IGF-2 in PMSCs differentiation into skeletal muscle is not
clearly defined and this study is the first to show the different effects between IGF-1 and
IGF-2. However, there is still a lot of work to be done to clearly define IGFs role and
determine the mechanism of the effects on PMSCs myogenesis and to confirm the
outcomes from this study, as experiments were performed from one preterm placental
tissue (15 weeks) and increasing the sample number to have biological replicates will
help confirm the results and better clarify the data.
In conclusion, PMSC differentiation into skeletal muscle is regulated by IGFs. IGF-1
delays PMSC commitment towards the muscle lineage while IGF-2 enhanced
myogenesis. IGFBP-6 was also required in this differentiation process and extracellular
addition of IGFBP-6 alongside IGF-2 inhibition rescued PMSCs muscle differentiation.
Since IGFBP-6 has both intracellular as well as extracellular effects, we show that effects
on muscle differentiation are both IGF-dependent and IGF-independent (particularly
IGF-2). Overall, treating PMSCs with IGFs and IGFBP-6 can regulate and improve
PMSC differentiation into skeletal muscle for tissue regeneration. Further investigation
of the balance between IGFs and IGFBP-6 is required to better understand PMSC-
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mediated myogenesis and testing the effects of these factors and their interactions with
the IGF-1R and insulin receptor are warranted to further delineate the signaling
mechanisms governing muscle lineage development and regeneration.

Figure 3.8. Model of IGFs and IGFBP-6 functions during PMSCs myogenesis.
During myogenesis, PMSCs lose pluripotency-associated markers (OCT4, SOX2, and
Nanog) and gain muscle commitment marker (Pax3/7) that decreased as muscle
differentiation markers increase (MyoG, MyoD, MHC). Committed and differentiated
muscle cells expressed IGF-1, IGF-2, and IGFBP-6. Extracellular IGF-1 increased
IGFBP-6 protein levels before PMSCs muscle commitment, resulting in a delayed
PMSCs muscle commitment and differentiation. However, IGF-2 extracellular increase
resulted in an increase in IGFBP-6 after commitment to the muscle lineage, resulting in
full muscle lineage differentiation. Increased IGF-2 and IGFBP-6 levels also had a
positive effect on OCT4 levels, but SOX2 and Nanog levels were decreased.
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Figure S3.1. PMSCs under muscle differentiation conditions treated with IGF1showed higher cell count, while IGF-2 treated PMSCs were lower compared to
PMSCs in muscle differentiation alone. Data is presented as the mean ± SEM of 15
different fields from 3 independent experiments from one preterm placenta (15 weeks).
One-way ANOVA followed by a Student‟s t-test was performed to determine
***P<0.001 comparing to muscle differentiation.
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Figure S3.2. IGF-2 siRNA treatment inhibited PMSCs differentiation into skeletal
muscle and adding extracellular IGFBP-6 with the treatment helped rescue muscle
compaction. (A) Compared to PMSCs under muscle lineage differentiation conditions
with siRNA scrambled control, (B) PMSCs under muscle differentiation conditions
treated with IGF-2 siRNA showed less skeletal muscle compaction at 14 days (20X). (C)
Extracellular IGFBP-6 supplementation with IGF-2 knockdown enhanced PMSCs
muscle compaction at 14 days compared to IGF-2 siRNA (shown with the whit arrow).
Images are representative of 3 technical replicate.
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Figure S3.3. IGFBP-6 levels secreted to the media increased with IGF-2 knockdown

compared to muscle differentiation using ELISA. Data is presented as the mean ±
SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test, ***=P<0.001.
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Figure S3.4. PMSCs treated with IGF-1 showed decreased IGF-2 levels secreted into
the media compared to muscle differentiation. Data is presented as the mean ± SEM
of 3 independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test, *P<0.05, ***=P<0.001.
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CHAPTER FOUR
Insulin-Like Growth Factor Binding Protein-6 Promotes the Differentiation of
Placental Mesenchymal Stem Cells into Skeletal Muscle Independent of the InsulinLike Growth Factor Receptor-1 and Insulin Receptor
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4.1 INTRODUCTION
Skeletal muscle comprises one-half of the human body (1). The development of skeletal
muscle is a complex multi-step process, starting with the generation of myogenic
precursors from mesodermal stem cells and ending with terminal differentiation and the
commitment of myoblasts into myofibers (2). During myogenesis, muscle stem cells
commit to muscle lineage by up-regulating muscle commitment markers (Pax3/7). As
Pax3/7 subsequently decreases, early muscle differentiation markers (MyoD and
Myogenin) begin to be expressed (3). The committed muscle cells then start to fuse and
form multinucleated fibers, which express the late muscle differentiation marker, myosin
heavy chain (MHC) (3). During muscle repair, a similar process is thought to occur
whereby satellite cells become activated, migrate towards injured muscle, and begin the
differentiation process to replace injured myofibers (4).
IGFs are important components of the skeletal muscle microenvironment and are
required for muscle growth during development and regeneration after injury (1, 5, 6).
IGFs regulate MyoD and Myogenin gene expression, but the mechanism is not
completely understood (1). When mice are injected with IGF-1, there is an enhancement
in muscle mass (hypertrophy) (7, 8). Moreover, IGF-1R null mice show profound muscle
hypoplasia and die prematurely soon after birth due to breathing difficulties resulting
from atrophy of diaphragm and respiratory muscles (9).
Following binding of IGFs to IGF-1R or IR, IRS-1 and IRS-2 are phosphorylated, then
PI3K-AKT-mTOR and MAPK pathways are activated (10). Therefore, crosstalk between
the different receptor tyrosine-kinase (RTK) pathways can lead to different cellular
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responses and signaling outcomes. Also, the presence of target effectors and the timing of
their activation are important in determining cell fate decisions towards proliferation or
differentiation (11).
During muscle differentiation, MAPK signals play an important role (12). Marshall et al.
reported that a prolonged activation of ERK1/2, leads to differentiation, whereas, a
transient activation of ERK1/2 leads to proliferation, as it is not sufficient to elevate the
levels of nuclear ERK1/2 (13). Therefore, the availability of growth factors in the
microenvironment and the receptors they activate determine stem cell fate through the
signaling intermediates activated. Furthermore, it is known that IGFs mediate and induce
myogenesis by directly activating the myogenin gene promoter. However, when the PI3K
inhibitor, LY294002, which acts upstream of AKT signaling is introduced, IGF is no
longer able to induce myogenesis or enhance the expression of myogenin (14). Therefore,
the direct effects of the IGF stimulation on the myogenin promoter are also mediated via
the actions of PI3K via AKT signaling. Additionally, IGF-1R signaling through PI3K
was shown to up-regulate myogenin expression leading to an enhanced myogenesis (14);
and also regulated basal levels of IGF-1 and IGF-2 genes during myogenesis (14, 15).
C2BP5 myoblast differentiation was still achieved when transfected by recombinant
adenoviruses expressing MyoD in the absence of IGFs (16). When MyoD-transfected
C2BP5 cells were treated with LY294002, the transcriptional activity of MyoD,
Myogenin, and MHC was not inhibited but the myofibers were smaller and thinner with
fewer nuclei (16). Collectively, these studies suggested that IGF-activated PI3K-AKT
and MAPK pathways are both important for myoblast differentiation (17).
IGFs interact with insulin for metabolism, survival, proliferation, and differentiation of
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many cell types either through IGF-1R or the insulin receptor (IR) or IGF-1R-IR hybrid
receptor (18-20). Both the IGF-1R and IR, are tyrosine protein kinases that activate
multiple signaling transduction pathways (20, 21). PI3K-AKT pathway but not the
MAPK is activated by insulin (21). It is known that each ligand binds to its respective
receptor with higher affinity and to the other receptor or hybrid receptors with lower
affinity. While IGFs play a major role in cellular proliferation, differentiation and
survival, and insulin has a major role in metabolism, their functions are interchangeable
depending on the concentration of the peptide in the extracellular space.
In RD rhabdomyosarcoma and LIM 1215 colon cancer cells, mutant IGFBP-6 that does
not bind to IGF-2 induces cellular migration, suggesting an IGF-independent function of
IGFBP-6 (22). Inhibition of ERK1/2 but not AKT impeded cellular migration (22). We
have previously reported that IGFBP-6, which has high affinity to IGF-2 (23, 24),
stimulates a multipotent profile and an early commitment to the muscle lineage in
PMSCs (Chapter Three). Furthermore, the impact of extracellular IGFBP-6 and silencing
of endogenous IGFBP-6 suggest that the biologic actions of IGFBP-6 occur in both IGFdependent and IGF-independent mechanisms (19, 25-27). The mechanisms of IGFdependent and IGF-independent actions are not yet delineated. In this study, we
demonstrated that the biologic actions of IGFBP-6 on PMSCs differentiation into skeletal
muscle occur independently of either IGFs or insulin signaling through IGF-1R or IR.
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4.2 MATERIALS AND METHODS

4.2.1 PMSC Isolation
PMSC isolation and experiments were conducted with the approval from the Health
Sciences Research Ethics Board of Western University (REB# 12154). Informed consent
was obtained from healthy women undergoing therapeutic termination of pregnancy, and
the PMSCs used in this study were isolated from one 15 week preterm placental tissue.
After surgery, chorionic villi were dissected, washed, and minced with surgical scissors
and forceps, and then subjected to enzymatic digestion with collagenase IV (369 IU/mg),
hyaluronidase (999 IU/mg) (Sigma-Aldrich, Oakville, ON), and DNase I (2,000 IU/mg)
(Hoffmann-LaRoche, Mississauga, ON) for 10 minutes at room temperature, followed by
0.05% trypsin (Gibco/Invitrogen, Mississauga, ON) for 5 minutes at room temperature.
The sample was then washed for 10 minutes with 10% FBS in DMEM/F12 medium and
the resulting single cell suspension was separated by density centrifugation over a Percoll
(Sigma-Aldrich, Oakville, ON) discontinuous gradient using a modified protocol by
Worton et al. (28).

4.2.2 Cell Culture
Cells from Percoll gradient fractions #3 and #4 were plated on to T75 flasks, cultured,
and maintained using DMEM/F12 media supplemented with 15% FBS serum
(Gibco/Invitrogen, Mississauga, ON) and FGF-2 (50 ng/mL) (Sigma-Aldrich, Oakville,
ON) containing 100 U/mL Penicillin, 100 µg/mL Streptomycin, and 0.25 µg/mL
Amphotericin-B. The non-adherent cells were discarded at the time of media change,
which was performed every 72 hours. The adherent cells were cultured until they reach
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90% confluence. Cells were then passaged 1:2 approximately once per week using 0.05%
Trypsin for 10 min at 37°C for 3 passages. Passaged cells were stored at -80°C in 1 mL
of freezing media (30% FBS and 10% DMSO in DMEM/F12 media). When needed,
vials were thawed and cells were resuspended in normal culture media (25 ng/mL FGF-2
and 15% FBS in DMEM/F12).

4.2.3 Muscle Differentiation and Treatments
Cells were plated in muscle growth media (fetal bovine serum 0.05 mL/mL, fetuin 50
µg/mL, epidermal growth factor 10 ng/mL, basic fibroblast growth factor 1 ng/mL,
insulin 10 µg/mL, and dexamethasone 0.4 µg/mL) for 48 hours before changing to the
skeletal muscle differentiation media, which is a proprietary serum-free medium
containing 10 µg/mL insulin (PromoCell, Heidelberg, Germany) for 14 days. Cells were
grown in six-well plates in a standard tissue culture incubator at 37°C in 5% CO2.
PMSCs were treated every 3 days with: 200 nM of the IGF-IR inhibitor, PPP (Santa Cruz
Biotechnology, Dallas, TX), 25 μM of the AKT inhibitor LY294002 (Santa Cruz
Biotechnology, Dallas, TX), 10 μM of the ERK1/2 inhibitor U0126 (Santa Cruz
Biotechnology, Dallas, TX), or 10 μM of the IR inhibitor HNMPA (Santa Cruz
Biotechnology, Dallas, TX) under muscle differentiation conditions. Treatment
concentrations for LY294002, U0126, and HNMPA were determined by a dose response
experiment using PMSCs in muscle differentiation media (Figure S4.1).
For IGFBP-6 supplementation with the inhibitors, recombinant human IGFBP-6
(PROSPEC, East Brunswick, NJ) was added to the media (375 ng/mL) every 3 days at

146

the time of media change. The IGFBP-6 concentration and time of supplementation was
determined as shown in Chapter 2 (Figure S2.1).

4.2.4 Cell Lysate Preparation
Following PMSC treatments, cells were washed with DPBS (Gibco/Invitrogen,
Mississauga, ON) and 200 μL of (1x) cell lysis buffer (Cell Signaling Technologies,
Burlington, ON) mixed with protease and phosphatase inhibitors (1:100) were added to
the cells. Cells were detached using a cell scraper and the lysate was sonicated for 15
seconds. Finally, samples were centrifuged for 15 min at 14,000 rpm at 4°C, and the
supernatant was collected.

4.2.5 Immunoblotting
Cell lysates containing 20 µg of protein were added to 6x SDS gel loading buffer (1% βmercaptoethanol, 1% SDS, 30% glycerol, 0.0012% bromophenol blue, Tris HCl 0.28 M,
pH 6.8). Samples were boiled for 5 minutes at 95oC, then placed on ice for 3 minutes,
and centrifuged at 3,000 rpm for 20 seconds before loading. Samples were resolved by
molecular weight using 10% SDS polyacrylamide gels transferred onto poly-vinyl-denefluoride (PVDF) membranes (Bio-Rad, Hercules, CA) using a Trans-Blot Turbo (BioRad, Hercules, CA) with an optimized protocol depending on protein size. Membranes
were blocked with 5% non-fat-dry milk, gently shaking for 1 hour at room temperature in
Tris-HCl buffer saline pH 8.0 with 0.1% Tween-20 (TBS-T). Blots were then washed
with TBS-T (3 times for 10 minutes) followed by incubation at 4°C overnight with
specific primary antibodies in 5% BSA or 5% non-fat-dry milk in TBS-T following the
manufacturer‟s protocol. To detect markers of cell potency, antibodies for OCT4
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antibody (N-19: sc-8628) (Santa Cruz Biotechnology, Dallas, TX), and SOX2 (2683-1)
(Epitomics, Burlington, ON) were used. To detect markers of muscle differentiation,
Pax3/7 (E-10: sc-365613), MyoD (M-318: sc-760), Myogenin (F5D: sc-12732), and
Myosin heavy chain (H-300: sc-20641) (Santa Cruz Biotechnology, Dallas, TX) were
used. To detect IGFBP-6, antibody H-70: sc-13094 (Santa Cruz Biotechnology, Dallas,
TX) was used. For loading control, pan-Actin Ab-5 (Thermo Fisher Scientific, Fremont,
CA) was used. To detect the activated signaling molecules, we used: phospho-p44/42
MAPK (#4377), p44/42 MAPK (#9102), phospho-AKT (Ser473, #4051), and AKT
(#9272) (Cell Signaling Technologies, Burlington, ON).
Then membranes were washed and incubated for 1 hour at room temperature with the
corresponding secondary HRP-conjugated antibody. The secondary antibodies used were
HRP-conjugated goat anti-rabbit (#170-6515) or anti-mouse (#170-6516) (Bio-Rad,
Hercules, CA) or donkey anti-goat antibody (Santa Cruz Biotechnology, Dallas, TX).
Resolved protein bands were detected using chemiluminescence and images were taken
using the VersaDoc Imager (Bio-Rad, Hercules, CA). Western blots were performed in
triplicate.

4.2.6 Immunocytochemistry
PMSCs were grown on glass cover slips (80-90% confluent) for 14 days, stained with
primary antibodies (1:100), and incubated at 4°C overnight. To detect markers of cell
potency, OCT4 antibody (N-19: sc-8628) (Santa Cruz Biotechnology, Dallas, TX) was
used. To detect markers of muscle differentiation, Myosin heavy chain (H-300: sc20641) (Santa Cruz Biotechnology, Dallas, TX) was used. To detect IGFBP-6, antibody
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H-70: sc-13094 (Santa Cruz Biotechnology, Dallas, TX) was used. Primary antibodies
were washed using 0.1% Tween-20 in PBS (3 times for 5 minutes); cells were then
incubated in the dark with the corresponding secondary AlexaFluor conjugated antibody
(1:200). The secondary antibodies used were AlexaFluor 488 or AlexaFluor 568
conjugated antibodies (Invitrogen, Mississauga, ON). The secondary antibody was
washed using 0.1% Tween-20 in PBS (3 times for 5 minutes), and the nuclear stain
(Hoechst dye) was added for 7 minutes and then rinsed. The cover slips were mounted
and images were taken using a confocal microscope (Zeiss, Germany). Each antibody
was immunostained in triplicates.

4.2.7 Quantification of IGFBP-6 and IGF-2 by Enzyme-Linked Immunosorbent
Assay (ELISA)
Human IGFBP-6 (RayBiotech®, Burlington, ON) and IGF-2 (ALPCO, Salem, NH)
ELISA kits were used to measure the amount of IGFBP-6 and IGF-2 secreted into
conditioned media at days 1, 3, 7, and 14. Standards and samples were loaded into the
wells (in triplicate) and the immobilized antibody bound IGFBP-6 or IGF-2 present in the
sample. The wells were washed and biotinylated anti-human antibody was added. After
washing, HRP-conjugated streptavidin was added; then a TMB substrate solution was
used to develop a blue color in proportion to the amount of IGFBP-6 or IGF-2 bound.
The Stop Solution changes color from blue to yellow, and the intensity was measured at
450 nm using Multiskan Ascent plate reader and analysis software.
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4.2.8 Aldehyde Dehydrogenase Activity (ALDH)
ALDH-activity, a conserved progenitor cell function, was assessed by flow cytometry at
days 1, 3, 7, and 14. Using the AldefluorTM assay (Stem Cell Technologies, Vancouver,
BC), as per the manufacturer‟s instructions. Briefly, 5 μL of activated Aldefluor reagent
was added to 1 mL of cell suspension and incubated for 45 minutes at 37°C. Cells were
washed and resuspended in 500 μL of ice-cold Aldefluor assay buffer and ALDH-activity
was measured using flow cytometry. As a negative control, AldefluorTM DEAB reagent
was used. Samples were run in triplicate (technical replicate).

4.2.9 Statistical Analysis
All experiments were performed in triplicate from one 15 week placental tissue (technical
replicates). GraphPad Prism Software 5.0 was used to generate all graphs and analyses. A
two-way ANOVA followed by a Bonferroni‟s multiple comparison test or a one-way
ANOVA followed by a Student‟s t-test was used to calculate significant differences when
p<0.05. Graphic representation values are presented as mean ± SEM (shown as variance
bars).

4.3 RESULTS

4.3.1 IGF-1R and IGFBP-6 are required for PMSCs Differentiation into Skeletal
Muscle
To evaluate the effects of IGF-1R inhibition on pluripotency-associated and muscle
differentiation markers in PMSCs under muscle differentiation conditions, PPP (IGF-1R
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auto phosphorylation inhibitor) was used during PMSCs muscle differentiation for 14
days with/without IGFBP-6 supplementation every 3 days. Using immunocytochemistry,
PPP treatment alone showed no changes in OCT4, IGFBP-6, and MHC immunoreactivity
at 14 days compared to muscle differentiation alone (Figure 4.1A). However, adding
IGFBP-6 together with PPP treatment showed higher IGFBP-6 and MHC
immunoreactivity at day 14 compared to PPP treatment alone (Figure 4.1A). Moreover,
PMSCs treated with IGFBP-6 together with PPP under muscle differentiation conditions
showed decreased cell numbers per field compared to muscle differentiation alone or PPP
alone, suggesting that IGFBP-6 may enhance muscle differentiation independent of IGFs
(Figure 4.1B).
As determined by immunoblotting, the presence of PPP decreased IGFBP-6 protein
levels at 14 days (Figure 4.2A). Pluripotency-associated markers (OCT4 and SOX2)
levels were decreased by PPP treatment compared to muscle differentiation alone (Figure
4.2B and 4.2C). The muscle commitment marker Pax3/7 levels were decreased by PPP
treatment at 7 and 14 days (Figure 4.2D). Similarly, muscle lineage differentiation
markers MyoD and MyoG protein levels were decreased at 7 and 14 days (Figure 4.2E
and 4.2F). In contrast, MHC levels were reduced at all-time points after PPP treatment
compared to muscle differentiation (Figure 4.2G). Overall, PPP treatment significantly
delayed muscle lineage commitment and differentiation in vitro.
To determine whether IGFBP-6 could rescue PMSCs differentiation into skeletal muscle
during IGF-1R inhibition, extracellular IGFBP-6 was added to the culture alongside PPP
supplementation. As predicted, IGFBP-6 levels increased after co-administration of
IGFBP-6 with PPP at day 14 compared to the inhibitor alone (Figure 4.2A). Also, OCT4
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protein levels were increased at 14 days with the combined treatments, while SOX2
levels were not changed compared to the inhibitor alone (Figure 4.2B and 4.2C).
Furthermore, IGFBP-6 supplementation with PPP, increased the levels of muscle lineage
differentiation markers Pax3/7, MyoD, MyoG, and MHC from 3-14 days compared to
PPP alone (Figures 4.2D to 4.2G). These findings suggest that IGFBP-6 may be an
important regulator of skeletal muscle differentiation and its action, in part, occurred
without activating IGF-1R signaling and independent of IGF.
Downstream of the IGF-1R signaling, the presence of PPP during muscle differentiation
caused a significant reduction in p-AKT levels at 7 days and in p-ERK1/2 levels at 7 and
14 days when compared to muscle differentiation alone (Figure 4.3A and 4.3B). In
contrast, IGFBP-6 increased both p-AKT and p-ERK1/2 protein levels at all-time points
in the presence of PPP under muscle differentiation conditions compared to PPP alone
indicating that IGFBP-6 may trigger MAPK signal transduction cascade independent of
IGFs (Figure 4.3A and 4.3B).
In the presence of PPP, IGFBP-6 secretion into the conditioned media was increased
compared to muscle differentiation (Figure 4.4A) whereas IGF-2 secretion was reduced
at days 3 and 7 (Figure 4.4B).
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Figure 4.1. PMSCs treated with extracellular IGFBP-6 and PPP showed
qualitatively more IGFBP-6 and MHC immunofluorescence with no change in
OCT4 expression at 14 days compared to PPP alone. (A) Compared to PMSCs
cultured with PPP alone, PMSCs treated with IGFBP-6 and PPP showed no change in
OCT4 immunoreactivity (green-Alexa, λ-488 nm), but increased IGFBP-6 and MHC
immunoreactivity (red-Alexa, λ-568 nm) compared to PPP alone. Nuclei, stained with
Hoechst dye (blue, λ=340 nm). Each antibody was performed in triplicate. (B) PMSCs
treated with PPP and IGFBP-6 showed reduced cell counts at 14 days compared to
PMSCs in muscle differentiation media alone and PMSCs with the inhibitor only. Data is
presented as the mean ± SEM of 3 independent experiments from one preterm placenta
and cell count was from 15 different fields. One-way ANOVA with a Student‟s t-test was
performed to determine ***P<0.001 compared to muscle differentiation, or
compared to PPP alone.

###

P<0.001
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Figure 4.2. PMSCs treated with the IGF-1R inhibitor, PPP, decreased pluripotencyassociated and muscle differentiation markers. (A) PPP treatment decreased IGFBP-6
protein levels at day 14 as compared to PMSCs grown in muscle differentiation media
only. IGFBP-6 supplementation with PPP increased IGFBP-6 levels at 1 and 14 days
compared to PPP alone. PPP treatment also decreased the protein levels of the
pluripotency-associated markers (B) OCT4 and (C) SOX2. When IGFBP-6 was added
with PPP, OCT4 levels increased at 14 days. (D) PPP treatment decreased the protein
levels of muscle lineage commitment marker Pax3/7 at 7 and 14 days. IGFBP-6
supplementation with PPP increased Pax3/7 from 3-14 days compared to PPP alone. (E,
F) Muscle differentiation markers, MyoD and MyoG, levels were decreased at 7 and 14
days, and adding IGFBP-6 with PPP reversed these effects. (G) Conversely, MHC
protein levels were reduced with PPP treatment at all-time points compared to muscle
differentiation. IGFBP-6 supplementation with PPP increased MHC levels from 3-14
days compared to PPP alone. Protein levels were quantified by densitometry and
normalized to β-Actin. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, **P<0.01, ***P<0.001 compared
to muscle differentiation conditions, or #P<0.05, ##P<0.01, ###P<0.001 compared to PPP.
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Figure 4.3. PMSCs treated with IGF-1R inhibitor (PPP) showed reduced p-AKT
and p-ERK1/2 levels that was reversed by IGFBP-6 addition. (A, B) PMSCs treated
with PPP showed lower protein levels of p-AKT p-ERK1/2 at the later time points when
compared to PMSCs under muscle differentiation conditions alone. When IGFBP-6 was
added to PPP, p-AKT and p-ERK1/2 levels increased at all-time points compared to PPP
alone. Protein levels were quantified by densitometry and normalized to total AKT or
total ERK1/2. Data is presented as the mean ± SEM of 3 independent experiments from
one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple comparison test
was performed to determine *P<0.05, **P<0.01, ***P<0.001 compared to muscle
differentiation conditions, or #P<0.05, ###P<0.001 compared to PPP.
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Figure 4.4. PMSCs treated with PPP showed increased IGFBP-6 secretion but
decreased IGF-2 secretion. (A) IGFBP-6 secretion was increased after PPP treatment at
all-time points compared to muscle differentiation conditions alone. (B) IGF-2 secretion
was reduced at 3 and 7 days compared to muscle differentiation conditions alone.
IGFBP-6 with PPP did not have an additional effect. Data is presented as the mean ±
SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test was performed to determine *P<0.05, **P<0.01,
***P<0.001 compared to muscle differentiation conditions alone.
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4.3.2 IGFBP-6 is required for PMSCs Muscle Differentiation after Inhibition of the
PI3K Pathway
To better understand downstream signaling of the IGF-1R, LY294002 was used to inhibit
PI3K signaling pathway. LY294002 alone reduced differentiated muscle morphology at 7
days (Figure 4.5 and S4.2). However, the addition of IGFBP-6 with LY294002 delayed
these changes until day 14 post-differentiation (Figure 4.5 and S4.2). Using
immunoblotting, IGFBP-6 expression was decreased at day 1 and 14 in the presence of
LY294002, and remained decreased despite IGFBP-6 supplementation (Figure 4.6A).
Furthermore, LY294002 treatment reduced the protein levels of the pluripotencyassociated markers OCT4 (Figure 4.6B) at day 1 and SOX2 (Figure 4.6C) at all-time
points as compared to muscle differentiation alone. After IGFBP-6 supplementation with
LY294002 treatment, OCT4 levels were maintained higher at all-time points; while
SOX2 expression was higher at day 14 compared to LY294002 treatment alone (Figure
4.6B and 4.6C). Muscle lineage markers MyoD, MyoG, and MHC levels decreased with
LY294002 treatment as compared to muscle differentiation alone (Figures 4.6D to 4.6F).
IGFBP-6 addition with LY294002 treatment increased MyoD protein levels at days 1 and
3 (Figure 4.6D); while MHC levels were increased compared to LY294002 treatment
alone (Figure 4.6F). These results indicated that muscle commitment occurred earlier in
the presence of IGFBP-6 with LY294002 treatment. To confirm this hypothesis, Pax3/7,
the muscle commitment marker expression was tested. Pax3/7 protein levels were
increased after IGFBP-6 addition with LY294002 (Figure 4.6G), suggesting an earlier
commitment to the muscle lineage when IGFBP-6 was present.
We used the AldefluorTM assay to determine the frequency of progenitor cells with high
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ALDH-activity, a more primitive progenitor phenotype. Compared to PMSCs under
muscle differentiation alone, there was a decrease in the frequency of cells with high
ALDH-activity (ALDH+ cells) in PMSCs treated with LY294002 until day 7 (Figure
4.7). Moreover, IGFBP-6 with LY294002 treatment reduced the frequency of cells with
high ALDH-activity at day 1 but was maintained at a higher number compared to
LY294002 alone at day 3. Therefore, IGFBP-6 prolonged progenitor phenotype in
PMSCs when PI3K pathway is inhibited under muscle differentiation conditions.
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Figure 4.5. PMSCs treated with LY294002 reduced differentiated muscle
compaction at 7 and 14 days, while IGFBP-6 with LY294002 delayed muscle
compaction changes to 14 days. PMSCs treated with LY294002, a PI3K inhibitor
upstream of AKT, under muscle differentiation conditions showed less skeletal muscle
morphology at 7 and 14 days; but the addition of IGFBP-6 with LY294002 delayed these
changes until day 14 (10X). Images are representative of 3 independent experiments from
one preterm placenta.
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Figure 4.6. LY294002 treatment reduced IGFBP-6, pluripotency-associated and
muscle differentiation markers. (A) IGFBP-6 protein levels decreased with LY294002
at day 1 and 14 as compared to muscle differentiation alone and adding extracellular
IGFBP-6 with the treatment did not cause additional changes to IGFBP-6 levels. (B, C)
PMSCs treated with LY294002 decreased OCT4 (at day 1) and SOX2 (at each time
point) compared to muscle differentiation, whereas IGFBP-6 addition with LY294002
increased OCT4 expression at 3, 7, and 14 days and at day 14 for SOX2 compared to
LY294002 alone. Muscle lineage differentiation markers protein levels were reduced
with LY294002 for (D) MyoD from 3-14 days, (E) MyoG at 7 and 14 days, and (F)
MHC at all-time points. IGFBP-6 supplementation with LY294002 increased MyoD
levels at 1 and 3 days and MHC levels at 3, 7, and 14 days compared to LY294002
treatment. (G) Pax3/7 protein levels decreased with LY294002 at day 7. IGFBP-6
addition with the inhibitor increased Pax3/7 levels until day 7. Protein levels were
quantified by densitometry and normalized to β-Actin. Data is presented as the mean ±
SEM of 3 independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test was performed to determine *P<0.05, **P<0.01,
***P<0.001 compared to muscle differentiation conditions, or
###

P<0.001 compared to LY294002, or

with IGFBP-6.

@@@

#

P<0.05,

##

P<0.01,

P<0.001compared to muscle differentiation
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Figure 4.7. PMSCs treated with LY294002 and LY294002 with IGFBP-6 under
skeletal muscle differentiation conditions decreased the frequency of cells with high
ALDH-activity. Representative flow cytometry dot plots showing the frequency of
PMSCs with high ALDH-activity when cultured under muscle differentiation conditions
with or without LY294002 or LY294002 and IGFBP-6 at (A) day 1, (B) day 3, (C) day 7,
and (D) day 14. DEAB treated controls were used to establish the ALDH gate (data not
shown). (E) Compared to PMSCs under muscle differentiation conditions, cells treated
with LY294002 showed a decreased frequency of cells with high ALDH-activity at 1, 3,
and 7 days. IGFBP-6 with LY294002 treatment decreased frequency of cells with high
ALDH-activity only at day1, and a significantly increased ALDH+ cells at day 3
compared to LY294002 treatment alone. Data is presented as the mean ± SEM of 3
independent experiments from one preterm placenta. Two-way ANOVA with
Bonferroni‟s multiple comparison test was performed to determine *P<0.05, ***P<0.001
compared to muscle differentiation, or
alone.

##

P<0.01,

###

P<0.001 compared to LY294002
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4.3.3 MAPK signaling is required for PMSC Differentiation into Skeletal Muscle
To test the downstream signaling of the IGF-1R via the MAPK pathway, U0126 was
used to inhibit MAPK signaling, which phosphorylates ERK1/2. PMSCs treated with
U0126 under muscle differentiation conditions showed reduced muscle cell compaction
from 3 to 14 days with a change in muscle morphology compared to PMSCs under
muscle differentiation alone. IGFBP-6 supplementation with U0126 treatment showed
similar morphology to U0126 alone (Figure 4.8 ). Using immunoblotting, IGFBP-6
levels were reduced with U0126 treatment and adding IGFBP-6 did not increase IGFBP6 levels, indicating that MAPK is an important pathway for IGFBP-6 production (Figure
4.9A). OCT4 levels were reduced at day 1 by U0126 alone or U0126 with IGFBP-6
addition; however, U0126 with IGFBP-6 treatment maintained higher levels of OCT4 at
7 and 14 days until a significant decrease at day 14 compared to U0126 alone (Figure
4.9B). In contrast, pluripotency-associated marker SOX2 protein levels were decreased
by U0126 until 7 days and were increased by IGFBP-6 at 7 and 14 days compared to
U0126 alone (Figure 4.9C). Early and late muscle lineage differentiation markers MyoD,
MyoG, and MHC protein levels were significantly reduced after day 3 with U0126 and
adding IGFBP-6 with U0126 did not reverse these effects (Figures 4.9D to 4.9F).
PMSCs treated with U0126 under muscle differentiation conditions decreased the
frequency of cells with high ALDH-activity compared to PMSCs under untreated muscle
differentiation condition at 1, 3, and 7 days (Figure 4.10). In contrast adding IGFBP-6
with U0126 treatment increased the frequency of cells with high ALDH-activity
compared to PMSCs treated with U0126 alone.
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Figure 4.8. PMSCs treated with U0126 under muscle differentiation conditions
showed reduced muscle compaction at 3 days. PMSCs under muscle differentiation
conditions with U0126, a MEK inhibitor upstream of ERK1/2, showed less skeletal
muscle differentiation at 3, 7, and 14 days with a change in cell morphology at 14 days
compared to muscle differentiation (10X). Images are representative of 3 independent
experiments from one preterm placenta.
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Figure 4.9. PMSCs treated with U0126 under muscle differentiation conditions
reduced

protein

levels

of

IGFBP-6,

pluripotency-associated

and

muscle

differentiation markers. (A) U0126 decreased IGFBP-6 protein levels and adding
IGFBP-6 with U0126 did not cause additional changes to IGFBP-6 levels. (B)
Pluripotency-associated marker OCT4 protein levels reduced with U0126 treatment at
day 1with increased levels at 7 days. IGFBP-6 addition with U0126 increased OCT4
levels at 3 and 7 days compared to U0126 treatment alone. (C) SOX2 protein levels were
lower at 1, 3, and 7 days compared to muscle differentiation. IGFBP-6 addition with
U0126 decreased SOX2 levels at day 1 with an increase at 7 and 14 days compared to
U0126. (D-F) Muscle differentiation markers MyoD, MyoG, and MHC protein levels
were decreased at the later time points with U0126 and adding IGFBP-6 with U0126 did
not change these effects. Protein levels were quantified by densitometry and normalized
to β-Actin. Data is presented as the mean ± SEM of 3 independent experiments from one
preterm placenta. Two-way ANOVA with Bonferroni‟s multiple comparison test was
performed to determine *P<0.05, **P<0.01, ***P<0.001 compared to muscle
differentiation, or #P<0.05, ##P<0.01, ###P<0.001 compared to U0126.
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Figure 4.10. PMSCs treated with U0126 and U0126 with IGFBP-6 under skeletal
muscle differentiation conditions decreased the frequency of cells with high ALDHactivity. Representative flow cytometry dot plots showing the frequency of PMSCs with
high ALDH-activity when cultured under muscle differentiation conditions with or
without either U0126 or U0126 and extracellular IGFBP-6 at (A) day 1, (B) day 3 , (C)
day 7 , and (D) day 14. DEAB treated controls were used to establish the ALDH gate
(data not shown). (E) U0126 treatment showed decreased frequency of cells with high
ALDH-activity at 1, 3, and 7 days compared to muscle differentiation alone. IGFBP-6
supplementation with U0126 increased frequency of cells with high ALDH-activity at 1,
3, and 7 days compared to U0126. Data is presented as the mean ± SEM of 3 independent
experiments from one preterm placenta. Two-way ANOVA with Bonferroni‟s multiple
comparison test was performed to determine *P<0.05, ***P<0.001 compared to muscle
differentiation, or ##P<0.01, ###P<0.001 compared to U0126.
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4.3.4 Inhibition of Insulin Receptor Signaling Delayed PMSCs Differentiation into
Skeletal and Adding IGFBP-6 Rescued the Effects
To test the role of insulin receptor (IR) signaling in the differentiation of PMSCs into
skeletal muscle, HNMPA, was used to block IR kinase activity. Neither HNMPA nor
HNMPA with IGFBP-6 impacted differentiated cell morphology when compared to
muscle differentiation conditions alone. However, HNMPA treatment delayed muscle
differentiation (less compaction) at day 14, compared to control treatment (Figure 4.11
and S4.3).
Intracellular IGFBP-6 levels were unchanged by HNMPA except for a reduction at day 7,
however adding IGFBP-6 with HNMPA increased IGFBP-6 protein levels at 3, 7, and 14
days (Figure 4.12A). HNPMA did not change protein levels of pluripotency-associated
markers (OCT4 and SOX2), but that addition of extracellular IGFBP-6 with HNMPA
increased both markers at days 7 and 14 compared to PMSCs under muscle
differentiation conditions and PMSCs treated with HNMPA (Figure 4.12B and 4.12C).
Additionally, muscle lineage differentiation markers (MyoD, MyoG, and MHC) levels
were decreased at the later time points with HNMPA compared to PMSCs under muscle
differentiation conditions, and extracellular IGFBP-6 increased MyoG and MHC levels at
7 and 14 days compared to HNMPA alone (Figures 4.12D to 4.12F).
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Figure 4.11. PMSCs under muscle differentiation conditions treated with HNMPA
show delayed muscle compaction at 14 days. PMSCs under muscle differentiation
conditions, with HNMPA or HNMPA with extracellular IGFBP-6, showed minimal
change in skeletal muscle morphology and density at day 14 when compared to muscle
differentiation (10X). Images are representative of 3 independent experiments from one
preterm placenta.
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Figure 4.12. PMSCs treated with HNMPA under muscle differentiation conditions
reduced muscle differentiation markers with no change in pluripotency-associated
markers. (A) HNMPA treatment decreased IGFBP-6 protein levels at 7 days as
compared to muscle differentiation. IGFBP-6 supplementation with HNMPA increased
IGFBP-6 levels at 3, 7, and 14 days. (B, C) HNMPA treatment did not change
pluripotency-associated markers OCT4 and SOX2 protein levels. IGFBP-6 with HNMPA
treatment increased the levels at 7 and 14 days. (D-F) HNMPA treatment decreased
muscle lineage differentiation markers MyoD, MyoG, and MHC protein levels at the
later time points (3- 14 days). IGFBP-6 addition with HNMPA treatment increased
MyoG and MHC levels at 7 and 14 days compared to HNMPA treatment alone. Protein
levels were quantified by densitometry and normalized to β-Actin. Data is presented as
the mean ± SEM of 3 independent experiments from one preterm placenta. Two-way
ANOVA with Bonferroni‟s multiple comparison test was performed to determine
*P<0.05, **P<0.01, ***P<0.001 compared to muscle differentiation conditions, or
#

P<0.05, ##P<0.01, ###P<0.001 compared to HNMPA.
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4.4 DISCUSSION
The promise of using stem cells in treating diseases is becoming closer to be used in the
clinic (29, 30). Still, understanding the niche factors and their influence on stem cell
proliferation and differentiation in vitro is essential before stem cells can be used safely
in regenerative medicine applications (31). Muscle differentiation is a multistep process,
starting with commitment to the muscle lineage and ending by the formation of
multinucleated myotubes (2). The IGF family is an essential early niche factor for stem
cell survival, growth, proliferation, and differentiation (23). It is also important in the
skeletal muscle niche, with a major role in muscle development (5, 6, 9). IGFBP-6 is
expressed in the developing cells (1). We have demonstrated that the balance between
intracellular and extracellular IGFBP-6 levels is required for modulating muscle
differentiation by PMSCs (Chapter Three) and that the effects of IGFBP-6 on muscle
differentiation are both IGF-dependent and IGF-independent (Chapter Four). These
findings provided basic insight into the role of IGFBP-6 and IGFs on PMSCs muscle
differentiation. The aim of this study was to characterize the effects of IGF-1R and IR
activation on the differentiation of PMSCs into skeletal muscle and to investigate IGFBP6 role in this process.
In these studies, we showed that IGF-1R inhibition using PPP decreased cellular IGFBP6, OCT4 and SOX2, and muscle differentiation markers MyoD, MyoG, and MHC levels.
These results indicated the importance of IGF-1R in PMSCs for IGFBP-6 localization,
maintaining a multipotent profile, and muscle differentiation. Importantly, IGFBP-6
supplementation stimulated PMSCs differentiation into muscle cells while IGF-1R was
inhibited as seen with the increased levels of muscle differentiation markers. These data
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indicate that IGFBP-6 was required for PMSCs muscle differentiation and its action may
be IGF-independent.
Triggering downstream phosphorylation of AKT or ERK1/2 independent of IGF-1R
activation by IGFBP-6 via an unknown mechanism could be responsible for IGFBP-6
impact on muscle cell differentiation. Inhibition of the PI3K pathway lowered IGFBP-6,
and the addition of extracellular IGFBP-6 did not increase intracellular IGFBP-6. This
indicates that the continuous inhibition of PI3K impacts muscle differentiation by
decreasing intracellular IGFBP-6 levels. The addition of extracellular IGFBP-6 when
PI3K was inhibited resulted in an earlier PMSC commitment to the muscle lineage
shown by increased Pax3/7 levels and decreased in ALDH+ cells frequency. Also,
IGFBP-6 combined treatment with PI3K-inhibition increased muscle differentiation, as
shown by increased MHC levels. We concluded that PI3K pathway is essential for
muscle differentiation, and when the pathway was inhibited, IGFBP-6 could overcome
the impact by allowing the cells to commit earlier to the muscle lineage and enhancing
late stage differentiation.
Blocking ERK1/2 phosphorylation with U0126 inhibited PMSCs differentiation into
skeletal muscle and IGFBP-6 addition did not rescue the muscle differentiation process.
These findings suggest that MAPK is a critical pathway for PMSCs skeletal muscle
differentiation and cannot be substituted by an alternative pathway. The fact that IGFBP6 did not accumulate in the intracellular environment when MAPK was inhibited shows
that PMSCs differentiation by IGFBP-6 was mediated via the MAPK pathway. It was
suggested previously that IGFBP-6 must be endogenously synthesized to have IGFindependent effects (32).
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Blocking insulin receptor, IR, using HNMPA delayed muscle differentiation of PMSCs
with no effect on pluripotency-associated markers. During IR-inhibition, IGFBP-6
addition improved the muscle differentiation and increased pluripotency-associated
markers protein levels suggesting that insulin or IGFs could trigger myogenic
differentiation; however, IGFBP-6 could also promote differentiation independent of
insulin or IGFs. These results are in agreement with previous reports on the importance
of IGF-1R, and its downstream pathways, and the IR in muscle development and
differentiation. However, this study is the first to show theses effects on human stem cells
isolated from the placenta and that IGFBP-6 addition enhanced the muscle differentiation
process of PMSCs when IGF-1R or IR were inhibited in vitro.
Different signaling pathways, including IGF-1R and IR, cross talk; and the complexity of
signaling and its effects on PMSCs differentiation into muscle is beyond the scope of one
study. The possibility that a different pathway, not examined in this study, is responsible
for IGFBP-6 effects on PMSCs differentiation into skeletal muscle must be considered
and further investigated to better understand IGFBP-6 role in this differentiation process.
Moreover, to confirm the results from this study, increasing the sample number to have
biological replicates is vital as experiments were performed from one preterm placental
tissue (15 weeks).
In conclusion, data presented in this study, suggest that both the IGF-1R and IR signaling
are important signaling pathways in PMSC differentiation towards skeletal muscle
lineage. In addition, IGFBP-6 was also important for differentiation to occur, due to a
combination of IGF-dependent and IGF-independent functions.
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Figure S4.1. PMSCs under muscle differentiation conditions treated with different
concentrations of PI3K, MAPK, and IR inhibitors. Cells were treated with different
concentrations of (A) LY294002 (PI3K inhibitor), (B) U0126 (MAPK inhibitor), or (C)
HNMAP (insulin receptor inhibitor) for 3 days under muscle differentiation conditions to
assess the optimal concentration to be used. The concentration of the inhibitors was selected
based on maintaining low band intensity for the duration of the experiment (3 days)
compared to muscle differentiation alone. 25 μM of the AKT inhibitor LY294002, 10 μM of
the ERK1/2 inhibitor U0126, and 10 μM of the IR inhibitor HNMPA were selected. Protein
levels were quantified by densitometry and normalized to total AKT, total ERK1/2, or βActin. Data is presented as the mean ± SEM of 3 independent experiments from one preterm
placenta. Two-way ANOVA with Bonferroni‟s multiple comparison test was performed to
determine *P<0.05, **P<0.01, ***P<0.001 compared to muscle differentiation conditions.
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Figure S4.2. Higher magnification of PMSCs treated with LY294002 or with
IGFBP-6 supplementation with LY294002. PMSCs treated with LY294002, a PI3K
inhibitor upstream of AKT, under muscle differentiation conditions showed less skeletal
muscle compaction at 7 days compared to muscle differentiation alone; but the addition
of IGFBP-6 with LY294002 delayed these changes (more compaction) as seen with the
white arrows compared to the inhibitor alone (20X). Images are representative of 3
independent experiments from one preterm placenta.

185

Figure S4.3. Higher magnification of PMSCs treated with HNMPA or with IGFBP6 supplementation with HNMPA. PMSCs treated with HNMPA under muscle
differentiation conditions showed less skeletal muscle compaction and density at 14 days
compared to muscle differentiation alone; but the addition of IGFBP-6 with HNMPA
showed more muscle compaction as seen with the white arrows compared to HNMPA
alone (20X). Images are representative of 3 independent experiments from one preterm
placenta.
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CHAPTER FIVE
DISCUSSION
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5.1 Summary and Perspective
The aim of this study was to determine if adult mesenchymal stem cells isolated from the
human placenta (PMSCs) have the capacity to differentiate into skeletal muscle, and to
delineate the effects of the insulin-like growth factor system, specifically IGFBP-6, IGF1, and IGF-2, on this differentiation process.
This study provides insights into the mechanisms of differentiation from PMSCs into
skeletal muscle by IGFs and IGFBP-6 during development, and highlights a potential
role for IGFBP-6 in regeneration therapy for skeletal muscle diseases. We found that
IGFBP-6 could regulate PMSC fate (multipotency or differentiation) in the presence or
absence of IGFs, particularly IGF-2. First, we validated that PMSCs possess multipotent
stem cells characteristics including the ability to differentiate into multiple mesodermal
lineages (Chapter Two). Second, we confirmed that PMSCs could also differentiate into
skeletal muscle and that IGFBP-6 played a role in the maintenance of a multipotent
profile and in the differentiation of PMSCs into skeletal muscle. Specifically, increased
extracellular IGFBP-6 before commitment to the muscle lineage maintained PMSC
multipotency alongside commitment to the muscle lineage, whereas a prolonged increase
in IGFBP-6 delayed late stage differentiation (Chapter Three). Third, IGFs, specifically
IGF-2, were required for PMSC muscle differentiation, and IGF-2 accelerated muscle
commitment and differentiation. Moreover, extracellular IGFBP-6 enhanced late stage
differentiation in the partial absence of IGF-2 before PMSCs muscle lineage commitment
(Chapter Four). Finally, we showed that MAPK signaling through IGF-1R was required
for muscle lineage differentiation. Also, IGFBP-6 promoted PMSCs differentiation into
muscle partly independent of PI3K and IR signaling pathways (Chapter Four).
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For use in regenerative therapies stem cells should be readily available, able to
differentiate predictably under lineage-specific conditions, well-tolerated by the host
without the induction of an immune response after transplantation, and will not promote
tumor formation. Adult mesenchymal stem cells isolated from the human placenta
possess all of these characteristics (1, 2). The PMSCs used for studies in this thesis were
isolated from the chorionic villi of preterm human placentae (15-20 weeks). In Chapter 2,
we confirmed that the PMSCs isolated from chorionic villi fulfill the minimal criteria for
the derivation of MSC by the International Society for Cellular Therapy (3-6). They were
plastic adherent, positive for mesenchymal markers CD73 and CD105, and differentiated
into osteoblasts, adipocytes, and myocytes in vitro. Therefore, this study confirms
previous reports that the chorionic villus of the human placenta is an ethical and readily
available source of adult MSCs for use in regeneration therapies (7-9).
We have shown that the IGF system is a central component of the stem cell niche
controlling both multipotency and muscle lineage differentiation in vitro. We believe that
modulation of this system during expansion in vitro may provide a novel therapeutic
strategy to generate progenitor cells suitable for use in skeletal muscle regenerative
therapies. In this thesis we focused on combined effects of ligands, receptors, and
binding-proteins (specifically IGFBP-6) of the IGF system, to direct the differentiation of
mesenchymal stem cells from preterm placenta (15 weeks). However, previous studies in
our lab showed that PMSCs from different gestational ages respond differently to IGFs
(10). Therefore, future studies are warranted to directly compare MSCs from the
chorionic villi of different gestations (preterm and full term human placentae), which will
further improve our understanding of skeletal muscle differentiation and the effects of the
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IGF system based on ontogeny, and will help in choosing the best gestation age PMSC
for skeletal muscle differentiation.

5.1.1 Role of the IGF System in PMSCs Multipotency and Muscle Differentiation
In this thesis, we manipulated several components of the IGF system during skeletal
muscle differentiation, in order to delineate the roles of specific components in muscle
differentiation. Our findings helped define the microenvironment needed by adult
mesenchymal stem cells to achieve and maintain skeletal muscle differentiation in vitro
and identify molecular mechanisms controlling IGF-signaling. We have demonstrated
that the IGF system plays an important role in determining adult MSCs fate, either
maintaining multipotency or progressing to differentiation in vitro.
Understanding the multipotency and differentiation processes, as well as the effects of
niche factors, are fundamental in stem cell biology and the utilization of stem cells in
regeneration therapies. Because the IGF system is expressed in the very early stages of
embryogenesis, at the pre-implantation stage, the IGF system is believed to be one of the
most important stem cell niche factors in embryonic or mesenchymal (adult) stem cell
development. As shown in previous studies, in human pregnancies, IGFs play an early
role in promoting proliferation and differentiation of placental cells (11), and reduced
levels of circulating IGFs during development lead to fetal growth restriction (12).
Furthermore, IGF-1R knockout mice have restricted growth and die prematurely due to
the lack of functional respiratory muscle (13-15).
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5.1.1.1 Roles of IGFBP-6
To date, no previous studies have reported the role of IGFBP-6 on the maintenance of
multipotency within adult mesenchymal stem cells or on the role of IGFBP-6 on the
differentiation of PMSCs into skeletal muscle. To achieve this goal we developed a
surrogate system to study the stages of muscle differentiation by PMSCs through
detection of the muscle commitment marker (Pax3/7) and myotubular proteins (MyoD,
MyoG, and MHC) to mark different stages of muscle development. We showed that as
PMSCs differentiate into skeletal muscle, they expressed greater levels of IGFBP-6 both
intracellularly (whole cell protein) and extracellularly (secreted to the media).
Overall, increased extracellular IGFBP-6 before muscle commitment enhanced
differentiation, whereas the continued expression of IGFBP-6 at later time points delayed
full myogenesis. Interestingly, pluripotency-associated markers were increased as
IGFBP-6 levels increased. In contrast, silencing IGFBP-6 using siRNA, which decreased
intracellular and extracellular IGFBP-6, significantly reduced pluripotency-associated
markers and delayed the expression of muscle differentiation markers at the early stages
of PMSCs differentiation into muscle. These findings suggested that extracellular
IGFBP-6 stimulates muscle lineage commitment while a prolonged exposure inhibits late
stage differentiation. In contrast, intracellular IGFBP-6 helped maintain OCT4 and
SOX2, delayed commitment, and enhanced differentiation. In summary, we suggest that
IGFBP-6 plays a dual role in both PMSC multipotency and in differentiation towards
muscle, with greater impact during the early stages of the differentiation process, before
muscle commitment has occurred. Also, the timing of the biologic actions of IGFBP-6
and the balance between intracellular and extracellular protein concentrations may
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represent an important regulatory mechanism in the differentiation of PMSCs into
skeletal muscle. Although in vivo studies are required to validate our findings, our study
is one of the first to show the role of IGFBP-6 on skeletal muscle lineage differentiation
in PMSCs.
These results support previous reports that IGFBP-6 is highly expressed in developing
muscle cells and is also abundant in differentiated skeletal muscle (16-18). However, the
role of IGFBP-6 in muscle development is unclear and IGFBP-6 was mostly investigated
in cancer cell lines. IGFBP-6 expression is associated with non-proliferative states and
inhibition of IGF-2-dependent tumor cell growth, such as rhabdomyosarcoma,
neuroblastoma, and colon cancer (19-21). Conversely, due to the fact that IGFs are rarely
found in the intracellular microenvironment, intracellular IGFBP-6 has IGF-independent
functions (22, 23). Therefore, IGFBP-6 was either secreted into the extracellular
microenvironment and interacted with the IGF peptides or IGFBP-6 was localized to the
intracellular microenvironment and functioned in an IGF-independent manner (22-24).

5.1.1.2 IGF-Dependent Functions of IGFBP-6
Our findings also suggest that IGF-1 and IGF-2 play different roles during PMSC
differentiation into skeletal muscle. We demonstrated that IGF-1 supplementation
increased IGFBP-6 protein levels within 24 hours but the effect was short-lived and after
3 days, the levels decreased. In contrast, IGF-2 supplementation increased IGFBP-6
levels more gradually throughout the 14-day time course. Therefore, by promoting an
immediate increase in intracellular IGFBP-6, IGF-1 delayed PMSC muscle commitment
as shown with the increased Pax3/7 protein levels. In contrast, IGF-2 by increasing
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IGFBP-6 levels gradually for a longer duration, promoted muscle differentiation. These
results suggested that IGF-1 and IGF-2 have direct effects on IGFBP-6 expression in
PMSCs during muscle differentiation. Although IGF-1 generally delayed PMSCs muscle
lineage commitment, IGF-2 acted to enhance muscle differentiation. IGFs may affect
differentiating PMSCs IGF-signaling directly or indirectly via IGFBP-6.
IGF-1 and IGF-2 stimulate both proliferation and terminal differentiation of many tissues
in developing embryos and adults. IGFBP-6 has a significantly higher affinity (~ 70-100
fold) for IGF-2 than IGF-1 (25-27). Interestingly, the site on IGF-2 where IGFBP-6 binds
overlaps with IGF-1R binding site, giving a structural basis for IGFBP-6 to inhibit IGF-2
binding to the IGF-1R (28). Studies in various cell lines have shown mostly an inhibitory
action of IGFBP-6 mainly via IGF-2-dependent actions. In L6A1 myoblast, IGFBP-6
inhibited muscle differentiation induced by IGF-2 but not IGF-1 (29). Previous reports on
the effects of IGFs on muscle differentiation were using mouse cell lines (30-36), thus
our study is one of the first to show the effects of IGF-dependent functions of IGFBP-6
on human mesenchymal stem cells differentiation into skeletal muscle in vitro.

5.1.1.3 IGF-Independent Functions of IGFBP-6
Our results also demonstrated that although IGF-2 was important for PMSCs
differentiation into skeletal muscle, IGFBP-6 extracellular supplementation with IGF-2
knockdown could compensate for IGF-2 loss and could enhance the differentiation
process independent of IGF-2 as seen with the increased levels of MyoD and MHC.
Our findings confirm previous reports that IGF-2 is required for myogenesis (37, 38).
Previous studies linked IGFBP-6 independent functions to regulate cell fate through the
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Ku proteins (23) and affect cancer cell migration and proliferation (25-27).This study is
the first to investigate the interaction between IGF-2 and IGFBP-6 on the early
differentiation stages of PMSCs into skeletal muscle.
In this thesis, we focused on the effects of IGFBP-6 on IGF-2, due to its higher affinity,
and how IGFBP-6 compensated for IGF-2 reduction under muscle differentiation
conditions. However, IGFBP-6 may also regulate IGF-1 availability, so the effects of
IGFBP-6 on IGF-1 need to be further delineated. For future studies, IGF-1 knockdown
combined with IGFBP-6 addition is necessary to compare to IGF-2 results. Moreover, we
showed that IGFBP-6 impacts on PMSCs muscle differentiation in both IGF-dependent
and IGF-independent manner. In future studies, use of a mutant IGFBP-6, that does not
bind IGF-2 and IGF-1 (18), would provide further evidence on the relative roles of IGFdependent and IGF-independent actions on skeletal muscle differentiation.

5.1.1.4 IGFBP-6 has IGF-1R-Dependent and –Independent Functions, but only IRIndependent Functions
In these studies, we also demonstrated that IGF-1R and its downstream signaling
pathways (PI3K-AKT and MAPK pathways) were required for PMSCs muscle
differentiation. We also showed that when the PI3K pathway was inhibited, increased
extracellular IGFBP-6 improved PMSC differentiation into skeletal muscle as seen with
the increased protein levels of MyoD and MHC. In contrast, MAPK pathway inhibition
could not be rescued by increased extracellular IGFBP-6 as seen with the unchanged
protein levels of muscle lineage differentiation markers. MAPK inhibition also caused a
significant decrease in intracellular IGFBP-6 concentrations, which could not be reversed
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by addition of extracellular IGFBP-6 as seen with the unaffected IGFBP-6 protein levels.
These studies suggested that MAPK signaling was an important pathway for PMSCs
differentiation into skeletal muscle, and that intracellular IGFBP-6 compliments this
process. Therefore, we suggest that in PMSCs, IGFBP-6 acts in an IGF-1R dependent
manner predominantly through the MAPK signaling pathway and not through PI3K to
achieve skeletal muscle differentiation. We further verified the importance of the insulin
receptor (IR) in PMSCs differentiation into muscle, and the interaction with IGFBP-6.
In this thesis, we also demonstrated that IR plays an important role in PMSC muscle
differentiation in addition to IGF-1R. We showed that inhibiting IR signaling delayed
PMSCs differentiation into skeletal muscle but did not completely block the process as
IGF-1R signaling was still active and most likely mediated the differentiation process.
These observations also suggested that the induction of muscle differentiation by the high
concentration of insulin (10 μg/mL) in the media is likely exerted by insulin binding to
the IGF-1R, to which it has low affinity binding capacity. The fact that IGFBP-6
enhanced muscle differentiation when IR was inhibited suggests that IGFBP-6 induced
PMSC differentiation into muscle could occur independent of IR signaling.
The IGF-1R and IR are both receptor tyrosine kinases that activate several signaling
transduction pathways (39, 40). IGFs and insulin both promote cell proliferation and
differentiation (37, 39-42), and IGFs also possess insulin-like metabolic effects,
including increased glucose uptake in skeletal muscle, mediated by either IGF-1R or IR
(43). Previous reports show that high concentrations of insulin activates both IGF-1R and
IR (30, 44), however, not much attention is given to IGF-1R binding affinity and effects
versus IR when insulin is used.
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Therefore, in future studies, a phospho-kinase array may be used to specify interacting
adaptors and signaling proteins within complementary IGF-1R and IR signaling
pathways. Also, alterations in the PMSCs microenvironment can cause epigenetic
changes; and it will be interesting to understand whether the IGF system affects
multipotency and myogenesis through epigenetic modulation of promoter regions.

5.2 Overall Conclusions
To date, previous studies on the role of the IGF family, specifically IGFBP-6, have not
been reported during the differentiation of PMSCs towards the skeletal muscle lineage.
The data presented in this thesis, gives insights into the effects of the IGF system on
PMSCs differentiation into skeletal muscle. By controlling the surrounding
microenvironment in vitro, PMSCs can be directed to proliferate or differentiate into
skeletal muscle in vitro. We have shown that the IGF family represents an early
important niche factors that regulates PMSCs stemness and differentiation.
PMSCs possess the ability to achieve terminal differentiation into skeletal muscle under
appropriate conditions. As summarized in Figure 5.1, this differentiation process is
regulated by the IGF family. During early myogenesis, PMSCs lose pluripotencyassociated markers (OCT4 and SOX2) and activate muscle commitment marker (Pax3/7).
During later stages of myogenesis, Pax3/7 was decreased as muscle differentiation
markers (MyoG, MyoD, and MHC) increased. A balance between IGF-1, IGF-2, IGFBP6, IGF-1R, and IR was required for complete muscle differentiation by PMSCs.
Extracellular and intracellular IGFBP-6 was expressed in PMSCs during differentiation,
and promoted PMSCs muscle differentiation in both an IGF-1R dependent and
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independent manner. The timing of manipulating the IGF system was crucial, as the
outcomes were different if performed before or after PMSCs commitment to the muscle
lineage. Thus, our findings indicated that IGFBP-6 regulates PMSC multipotency and
differentiation into muscle in a time-dependent manner, with more prominent effects
observed at the beginning of the differentiation process, before muscle lineage
commitment.
Overall, manipulating the PMSCs microenvironment using the IGF system, particularly
IGFBP-6, can improve PMSC myogenic differentiation, a first step towards PMSC use
for muscle regeneration therapies.

5.3 Limitations and Future Studies
This study is the first to provide fundamental insight into the effects of the IGF system on
PMSCs differentiation into skeletal muscle. Therefore, further experiments are required
to address the limitations and to further delineate mechanistic interactions. Based on data
presented throughout this study, future studies can be planned as follows:

5.3.1 IGFBP-6 and IGF-2 Silencing
When siRNA was used to knockdown IGFBP-6 and IGF-2 expression, only partial
knockdown was achieved, as the protein levels of IGFBP-6 and IGF-2 were not
completely diminished. Also, expression of each protein was restored back to control
levels even with the continuous addition of siRNA every 3 days. Therefore, alternate
methods to knockdown IGFBP-6 and IGF-2 expression is needed to improve gene
silencing. For example, the use of IGFBP-6- or IGF-2-specific shRNAs, or CRISP/Cas9
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gene editing technologies would improve the interpretation of data generated using our in
vitro muscle differentiation system. The use of IGFBP-6 and IGF-2 shRNAs has
previously been shown to induce a significant and stable down-regulation of mRNA and
protein in primary human cells (45, 46).

5.3.2 The Role of OCT4 in PMSCs Muscle Differentiation
In our study, we found that OCT4 behaved differently than other pluripotency-associated
markers. OCT4 expression was positively affected by IGFBP-6 and increased alongside
muscle differentiation markers with IGFBP-6 treatment. Therefore, inhibiting or
overexpressing OCT4 would further delineate its role in response to IGFs and IGFBP-6
in PMSCs under muscle differentiation conditions (47, 48). OCT4 localization and dose
is important for its function (49); thus nuclear versus cytoplasmic fractionation
experiments would be required to show if continued OCT4 expression during PMSCs
muscle differentiation was relevant to OCT4 associated transcriptional activities.

5.3.3 PMSCs and IGFBP-6 Therapeutic Potential in vivo
In future experiments, mouse models with muscle injury can be used to test PMSCs and
IGFBP-6 affects in vivo. We can test the effects of priming PMSCs with IGFBP-6 during
their differentiation into skeletal muscle for engraftment or IGFBP-6 injections.
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Figure 5.1. PMSCs differentiation into skeletal muscle using the insulin-like growth
factor system. PMSCs isolated from the chorionic villus of preterm human placenta (15
weeks) expressed high levels of pluripotency-associated markers (OCT4 and SOX2)
under normal growth conditions (10% FBS). As these cells differentiated into skeletal
muscle, the levels of these markers decreased and the cells committed to the muscle
lineage, indicated by Pax3/7 expression. Once committed to differentiation, PMSCs
subsequently decreased Pax3/7 expression and increased muscle differentiation markers
(MyoG, MyoD, and MHC) as myoblasts aligned and fuse to form multinucleated
myofibers. IGF-1 and IGF-2 binds to the IGF-1R and activates its intrinsic tyrosine
kinase activity resulting in signaling that accelerated muscle differentiation via
downstream signals including PI3K-AKT-mTOR and the RAF-MEK-ERK (MAPK)
pathway. Due to IGFBP-6 intracellular and extracellular locations, IGFBP-6
demonstrated both IGF-dependent and IGF-independent effects on PMSCs muscle
differentiation. Extracellular IGFBP-6 binds IGFs and enhances the muscle
differentiation process through the IGF-1R, while intracellular IGFBP-6 directly
impacted PMSCs muscle differentiation through an unknown mechanism.
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5.4 Significance
Knowledge on how myogenesis can be manipulated through IGFs and IGFBP-6 will help
elucidate the mechanisms controlling MSC fate and thus will help us improve strategies
for skeletal muscle regeneration therapies using stem cells from human placenta in
myogenic diseases to rescue muscle loss.
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Appendix 4
Characterization of Placental Mesenchymal Stem Cells
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MATERIALS AND METHODS

Isolation of PMSCs
PMSC isolation and experiments were conducted with the approval from the Health
Sciences Research Ethics Board of Western University (REB# 12154). Informed consent
was obtained from healthy women undergoing therapeutic termination of pregnancy, and
the PMSCs used in this study were isolated from one 15 week preterm placental tissue.
After surgery, chorionic villi were dissected, washed, and minced with surgical scissors
and forceps, and then subjected to enzymatic digestion with collagenase IV (369 IU/mg),
hyaluronidase (999 IU/mg) (Sigma-Aldrich, Oakville, ON), and DNase I (2,000 IU/mg)
(Hoffmann-LaRoche, Mississauga, ON) for 10 minutes at room temperature, followed by
0.05% trypsin (Gibco/Invitrogen, Mississauga, ON) for 5 minutes at room temperature.
The sample was then washed for 10 minutes with 10% FBS in DMEM/F12 medium and
the resulting single cell suspension was separated by density centrifugation over a Percoll
(Sigma-Aldrich, Oakville, ON) discontinuous gradient using a modified protocol by
Worton et al. Cells from Percoll gradient fractions #3, #4, and #5 were plated on to T75
flasks, cultured, and maintained using DMEM/F12 media supplemented with 15% FBS
serum (Gibco/Invitrogen, Mississauga, ON) and FGF-2 (50 ng/mL) (Sigma-Aldrich,
Oakville, ON) containing 100 U/mL Penicillin, 100 µg/mL Streptomycin, and 0.25
µg/mL Amphotericin-B. The non-adherent cells were discarded at the time of media
change, which was performed every 72 hours. The adherent cells were cultured until they
reach 90% confluence. Cells were then passaged 1:2 approximately once per week using
0.05% Trypsin for 10 min at 37°C for 3 passages. Passaged cells were stored at -80°C in
1 mL of freezing media (30% FBS and 10% DMSO in DMEM/F12 media). When
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needed, vials were thawed and cells were resuspended in normal culture media (25
ng/mL FGF-2 and 15% FBS in DMEM/F12).

Osteogenic differentiation
Cells were grown in 6-well plates (90% confluent) in osteogenic differentiation media
(MesenCult basal medium, osteogenic differentiation promoting supplements, ascorbic
acid, β-glycerophosphate and dexamethasone) purchased from Stem Cell Technologies
(Vancouver, BC). Media was changed every 3 days. After three weeks, cells were fixed
using 100% ice cold ethanol for 30 minutes, then dried at room temperature. The wells
were stained with 1 mL of 0.01% of alizarin red for 40 minutes at room temperature. The
staining was observed under an inverted light microscope (Zeiss, Germany). Cells grown
in 10% FBS media (Gibco-Invitrogen, Mississauga, ON) were used as negative controls.
The staining of the cells was solubilized using 1mL of 10% cetylpyridium phosphate in
10 nM sodium phosphate pH 7.0 and the absorbance of a 200 μL reaction volume was
read at λ=570 nm using a plate reader-spectrophotometer.

Adipogenic Differentiation
Cells were grown in 6-well plates (90% confluent) in adipogenic differentiation media
(StemPro basal medium, adipogenesis supplements, Gentamicin reagent) from GibcoInvitrogen (Mississauga, ON) for three weeks. Media was changed every 3 days Cells
were fixed with 100% ice cold ethanol for an hour, then 60% Isopropanol was added for
5 minutes before staining with oil red O for an hour. Finally, hematoxylin stain was
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added for one minute to stain nuclei. Cells grown in 10% FBS (Gibco-Invitrogen,
Mississauga, ON) media were used as negative controls.

Flow Cytometry Analysis
Cells were trypsinized for 10 minutes using recombinant trypsin (TripleXExpress, GibcoInvitrogen, Mississauga, ON) diluted 1:1 in PBS, at 37ºC. After the cells were detached
from the flask, trypsin was neutralized with 10% FBS in DMEMF/12 medium, cells were
washed and incubated for one hour with fluorochrome labeled primary antibody against
MSCs markers. CD73 (#550256) (BD Pharmingen, San Jose, CA), PE conjugated
CD105 (#12-1057-73) (eBioscience, San Diego, CA), and CD-117/c-Kit (sc-13508)
(Santa Cruz Biotechnology, Dallas, TX) were used.

Statistical Analysis
All experiments were performed in triplicate from two 15 or 20 weeks placental tissue
(technical and biological replicates). GraphPad Prism Software 5.0 was used to generate
all graphs and analyses. A two-way ANOVA followed by a Bonferroni‟s multiple
comparison test was used to calculate significant differences when p<0.05. Graphic
representation values are presented as mean ± SEM (shown as variance bars).
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RESULTS

PMSCs Isolated from Placental Tissue Showed Stem Cell Characteristics
Mesenchymal stem cells from preterm placenta (15-20 weeks) were isolated and
characterized.

Following cell expansion on tissue culture plastic, cell identity was

verified by flow cytometry for the MSCs multipotency markers CD105 (>95%), CD73
(>95%), and CD117 (c-Kit) (<10%).
Mesenchymal stem cells from three preterm placentae were isolated; two from the late
first trimester of pregnancy (15 weeks) (Figure 6.1) and one from the second trimester
(20 weeks) (Figure 6.2). Cells were collected from layers 3, 4, and 5 based on the Percoll
gradient density (Figures 6.1A and 6.2A). In vitro, the cells isolated were plastic adherent
(Figure 6.1B and 6.2B). Stem cell markers CD73, CD105, and CD117 were measured
using flow cytometry (Figures 6.1C and 6.2C).
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Figure 6.1. PMSC Isolation from 15 weeks preterm placenta. (A) The dissected
villous tissue was digested enzymatically and cells were separated using a discontinuous
Percoll gradient. Five cell fractions were typically obtained corresponding to five
different densities and cells were isolated from layers 3, 4, and 5. (B) Phase contrast
images of the isolated PMSCs, from all three layers, grown in culture after 4 weeks. (C)
PMSCs from passage 4 of all three layers were positive for CD73 and CD105 (>98%),
and were negative for CD117 (<1%) (measured by flow cytometry).

Flow cytometry

histograms are representative of all 3 layers from one placental tissue as they showed the
same results.
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Figure 6.2. PMSC Isolation from 20 weeks preterm placenta. (A) Successful cell
separation using Percoll gradient. Five cell fractions were obtained and cells were
isolated from layers 3, 4, and 5. (B) Phase contrast images of the isolated PMSCs, from
all three layers, grown in culture after 4 weeks. (C) PMSCs from passage 4 of all three
layers were positive for CD73 and CD105 (>98%), and were negative for CD117 (<1%)
(measured by flow cytometry). Flow cytometry histograms are representative of all 3
layers from one placental tissue as they showed the same results.
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PMSCs Demonstrate Osteogenic and Adipogenic Differentiation Competence
PMSCs isolated from preterm placentae (15-20 weeks) tissue were cultured and
maintained in a standard tissue culture incubator using DMEM/F12 media supplemented
with 10% fetal bovine serum (FBS) in tissue culture flasks until they reached 60%
confluency. Cells were then cultured in 6-well plates in either osteogenic or adipogenic
differentiation media. Cells grown in 10% FBS media were used as negative controls.
After 20 days in culture, cells were fixed and stained for differentiation markers. Alizarin
red was used for osteogenic differentiation and oil red O for adipogenic differentiation.
All three layers of isolated PMSCs formed multilayered structures in which calcium
deposits were detected by alizarin red staining from both 15 weeks (Figure 6.3A) and 20
weeks PMSCs (Figure 6.3B). Adipogenic differentiation was also achieved for all three
layers, as seen with oil red O staining and the formation of round adipocytes for both
gestational age PMSCs (Figure 6.4A and 6.4B).
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(B)

Figure 6.4. PMSCs from different gestational ages differentiate towards the
osteogenic lineage. PMSCs isolated from all three layers showed osteogenic
differentiation when cultured in osteogenic medium, as measured by the accumulation of
calcium deposits shown with alizarin red staining in cells isolated from (A) 15 weeks and
(B) 20 weeks placenta samples compared to untreated control at 3 weeks (10x
magnification). The lower panel shows alizarin red staining quantification. Data are
representative of three independent experiments from one placenta per gestational age.
(Two-way ANOVA followed by a Bonferroni‟s multiple comparison test, ***=P<0.001).
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Figure 6.5. PMSCs isolated from different gestational ages differentiate towards the
adipogenic lineage. Cells isolated from 15 week (A) and 20 week (B) placentae, were
cultured in adipogenic medium or left untreated (control) for 21 days. All three layers
showed the ability to differentiate into adipocytes shown by the accumulation of lipid
droplets within the cells with the oil red O staining. Results are representative of three
independent experiments from one placenta per gestational age.
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Conclusion
We isolated PMSCs based on density gradient separation and growth adherence to tissueculture plastic. Moreover, cultured PMSCs were positive for the mesenchymal markers
CD73 and CD105 (>95%) and did not express the hematopoietic marker c-kit (<10%).
Furthermore, PMSCs isolated from the chorionic villi of preterm placental tissue (at 15
weeks and 20 weeks) differentiated into osteoblasts and adipocytes; confirming
multipotent differentiation of PMSCs. Thus, PMSCs represent a promising cell type for
the development of tissue regeneration therapy, due to early ontogeny and multipotent
potential.
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